| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Fluorobenzenes | 28 | 2015 | 179 | 4.340 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 67 | 2024 | 3253 | 3.510 |
Why?
|
| Pharmacoepidemiology | 24 | 2024 | 352 | 3.230 |
Why?
|
| Propensity Score | 37 | 2023 | 1971 | 2.830 |
Why?
|
| Sulfonamides | 29 | 2015 | 1988 | 2.520 |
Why?
|
| Comparative Effectiveness Research | 14 | 2019 | 712 | 2.510 |
Why?
|
| Cardiovascular Diseases | 117 | 2024 | 15638 | 2.510 |
Why?
|
| Models, Statistical | 32 | 2021 | 5103 | 2.220 |
Why?
|
| C-Reactive Protein | 54 | 2023 | 3854 | 2.160 |
Why?
|
| Pyrimidines | 29 | 2017 | 3050 | 2.150 |
Why?
|
| Epidemiologic Methods | 18 | 2017 | 1337 | 2.080 |
Why?
|
| Dipeptidyl-Peptidase IV Inhibitors | 12 | 2024 | 317 | 1.700 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 38 | 2020 | 2279 | 1.690 |
Why?
|
| Research Design | 23 | 2024 | 6217 | 1.450 |
Why?
|
| Myocardial Infarction | 61 | 2024 | 11515 | 1.450 |
Why?
|
| Methotrexate | 14 | 2024 | 1722 | 1.430 |
Why?
|
| Psoriasis | 5 | 2024 | 947 | 1.410 |
Why?
|
| Venous Thromboembolism | 15 | 2022 | 1884 | 1.380 |
Why?
|
| Cholesterol, LDL | 34 | 2024 | 2396 | 1.360 |
Why?
|
| Interleukin-1beta | 13 | 2022 | 1021 | 1.330 |
Why?
|
| Diabetes Mellitus, Type 2 | 41 | 2024 | 12242 | 1.330 |
Why?
|
| Data Interpretation, Statistical | 29 | 2020 | 2705 | 1.330 |
Why?
|
| Cataract | 28 | 2024 | 837 | 1.330 |
Why?
|
| Aged | 421 | 2024 | 171520 | 1.290 |
Why?
|
| Primary Prevention | 19 | 2024 | 1189 | 1.240 |
Why?
|
| Venous Thrombosis | 12 | 2020 | 1318 | 1.210 |
Why?
|
| Hypertension | 55 | 2023 | 8611 | 1.210 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 13 | 2020 | 321 | 1.190 |
Why?
|
| Blood Pressure | 38 | 2019 | 8538 | 1.190 |
Why?
|
| Vitamin E | 19 | 2022 | 873 | 1.180 |
Why?
|
| Double-Blind Method | 94 | 2024 | 12450 | 1.170 |
Why?
|
| Mortality | 27 | 2024 | 2917 | 1.140 |
Why?
|
| Randomized Controlled Trials as Topic | 50 | 2023 | 10358 | 1.130 |
Why?
|
| Insurance Claim Review | 13 | 2021 | 745 | 1.050 |
Why?
|
| Warfarin | 18 | 2024 | 1493 | 1.030 |
Why?
|
| Humans | 657 | 2024 | 768451 | 1.030 |
Why?
|
| Incidence | 95 | 2024 | 21552 | 0.980 |
Why?
|
| Hypoglycemic Agents | 23 | 2024 | 3111 | 0.970 |
Why?
|
| Medicare | 54 | 2024 | 6881 | 0.970 |
Why?
|
| Frail Elderly | 12 | 2024 | 774 | 0.960 |
Why?
|
| Atherosclerosis | 16 | 2024 | 3431 | 0.960 |
Why?
|
| Middle Aged | 350 | 2024 | 223418 | 0.940 |
Why?
|
| Cohort Studies | 112 | 2024 | 41797 | 0.930 |
Why?
|
| Risk Factors | 203 | 2024 | 74915 | 0.920 |
Why?
|
| Insurance, Pharmaceutical Services | 11 | 2013 | 348 | 0.910 |
Why?
|
| Female | 416 | 2024 | 396943 | 0.890 |
Why?
|
| Regression Analysis | 36 | 2023 | 6353 | 0.890 |
Why?
|
| Coronary Disease | 26 | 2024 | 5926 | 0.890 |
Why?
|
| Patient Compliance | 22 | 2012 | 2696 | 0.880 |
Why?
|
| Computer Simulation | 21 | 2023 | 6278 | 0.880 |
Why?
|
| Male | 434 | 2024 | 364781 | 0.860 |
Why?
|
| Aspirin | 34 | 2011 | 3139 | 0.860 |
Why?
|
| Anticoagulants | 21 | 2024 | 4840 | 0.820 |
Why?
|
| Vitamins | 15 | 2022 | 1638 | 0.810 |
Why?
|
| Hidradenitis Suppurativa | 2 | 2024 | 179 | 0.810 |
Why?
|
| Macular Degeneration | 18 | 2020 | 1016 | 0.810 |
Why?
|
| Statistics, Nonparametric | 9 | 2018 | 2863 | 0.800 |
Why?
|
| United States | 157 | 2024 | 73121 | 0.790 |
Why?
|
| Cost Sharing | 7 | 2008 | 409 | 0.770 |
Why?
|
| Aged, 80 and over | 185 | 2024 | 59680 | 0.760 |
Why?
|
| Vitiligo | 1 | 2022 | 100 | 0.750 |
Why?
|
| Arthritis, Rheumatoid | 15 | 2024 | 3763 | 0.740 |
Why?
|
| Dermatitis, Atopic | 3 | 2024 | 734 | 0.740 |
Why?
|
| Epidemiologic Studies | 2 | 2021 | 681 | 0.740 |
Why?
|
| Antihypertensive Agents | 27 | 2023 | 2028 | 0.730 |
Why?
|
| Proportional Hazards Models | 70 | 2024 | 12561 | 0.720 |
Why?
|
| Pulmonary Embolism | 10 | 2022 | 2591 | 0.710 |
Why?
|
| New Jersey | 27 | 2011 | 295 | 0.710 |
Why?
|
| Likelihood Functions | 11 | 2023 | 993 | 0.710 |
Why?
|
| Stroke | 33 | 2024 | 9791 | 0.710 |
Why?
|
| Epidemiologic Research Design | 8 | 2014 | 368 | 0.680 |
Why?
|
| Alopecia Areata | 1 | 2022 | 130 | 0.680 |
Why?
|
| Antirheumatic Agents | 10 | 2024 | 1374 | 0.650 |
Why?
|
| Hypercholesterolemia | 7 | 2018 | 1142 | 0.650 |
Why?
|
| Biometry | 5 | 2010 | 565 | 0.640 |
Why?
|
| Cholesterol, HDL | 21 | 2022 | 1820 | 0.640 |
Why?
|
| Cause of Death | 23 | 2024 | 3727 | 0.630 |
Why?
|
| Heart Failure | 29 | 2024 | 11857 | 0.630 |
Why?
|
| Hyperlipidemias | 9 | 2023 | 773 | 0.600 |
Why?
|
| Antioxidants | 18 | 2020 | 1678 | 0.590 |
Why?
|
| Benzhydryl Compounds | 5 | 2024 | 939 | 0.590 |
Why?
|
| Acetaminophen | 4 | 2020 | 556 | 0.590 |
Why?
|
| Biostatistics | 4 | 2024 | 165 | 0.570 |
Why?
|
| Metformin | 6 | 2023 | 914 | 0.570 |
Why?
|
| Gout | 7 | 2023 | 621 | 0.570 |
Why?
|
| Thromboembolism | 7 | 2018 | 1006 | 0.560 |
Why?
|
| Follow-Up Studies | 105 | 2024 | 39430 | 0.560 |
Why?
|
| Glucosides | 5 | 2024 | 532 | 0.560 |
Why?
|
| Atrial Fibrillation | 15 | 2024 | 5162 | 0.560 |
Why?
|
| Comorbidity | 26 | 2018 | 10601 | 0.530 |
Why?
|
| Eye Diseases | 7 | 2024 | 657 | 0.520 |
Why?
|
| Geriatric Assessment | 8 | 2020 | 1422 | 0.510 |
Why?
|
| Cholesterol | 17 | 2023 | 2910 | 0.510 |
Why?
|
| Arthritis, Psoriatic | 1 | 2018 | 220 | 0.510 |
Why?
|
| Risk Assessment | 50 | 2024 | 24311 | 0.510 |
Why?
|
| Ascorbic Acid | 9 | 2022 | 658 | 0.500 |
Why?
|
| Sample Size | 7 | 2024 | 851 | 0.490 |
Why?
|
| beta Carotene | 15 | 2009 | 523 | 0.480 |
Why?
|
| British Columbia | 16 | 2012 | 241 | 0.480 |
Why?
|
| Causality | 8 | 2023 | 1255 | 0.480 |
Why?
|
| Logistic Models | 46 | 2021 | 13324 | 0.480 |
Why?
|
| Interleukin-6 | 6 | 2022 | 3234 | 0.480 |
Why?
|
| Antibodies, Monoclonal | 8 | 2021 | 9263 | 0.470 |
Why?
|
| Prospective Studies | 99 | 2024 | 54914 | 0.470 |
Why?
|
| Mendelian Randomization Analysis | 2 | 2010 | 1036 | 0.460 |
Why?
|
| Drug Costs | 8 | 2012 | 1196 | 0.460 |
Why?
|
| Algorithms | 19 | 2024 | 14158 | 0.460 |
Why?
|
| Lipoproteins, LDL | 5 | 2020 | 644 | 0.450 |
Why?
|
| Systole | 10 | 2011 | 938 | 0.450 |
Why?
|
| Hypolipidemic Agents | 7 | 2022 | 609 | 0.450 |
Why?
|
| Adult | 193 | 2024 | 223542 | 0.450 |
Why?
|
| Physicians | 36 | 2022 | 4615 | 0.450 |
Why?
|
| Women's Health | 13 | 2018 | 2079 | 0.440 |
Why?
|
| Visual Acuity | 28 | 2020 | 2714 | 0.440 |
Why?
|
| Government Regulation | 1 | 2018 | 525 | 0.440 |
Why?
|
| Dietary Supplements | 15 | 2024 | 3445 | 0.440 |
Why?
|
| Multivariate Analysis | 33 | 2018 | 12096 | 0.430 |
Why?
|
| Cluster Analysis | 6 | 2010 | 2731 | 0.430 |
Why?
|
| Anticholesteremic Agents | 9 | 2017 | 972 | 0.430 |
Why?
|
| Methylenetetrahydrofolate Reductase (NADPH2) | 2 | 2012 | 276 | 0.430 |
Why?
|
| Osteoarthritis | 6 | 2024 | 1070 | 0.430 |
Why?
|
| Medicare Part D | 6 | 2013 | 358 | 0.430 |
Why?
|
| Risk | 51 | 2016 | 9642 | 0.430 |
Why?
|
| Treatment Outcome | 68 | 2024 | 65409 | 0.420 |
Why?
|
| Hemorrhage | 11 | 2024 | 3458 | 0.420 |
Why?
|
| Colitis, Ulcerative | 2 | 2022 | 1930 | 0.420 |
Why?
|
| Platelet Aggregation Inhibitors | 12 | 2024 | 2768 | 0.420 |
Why?
|
| Prescription Drugs | 7 | 2024 | 634 | 0.410 |
Why?
|
| Electronic Health Records | 10 | 2024 | 4877 | 0.410 |
Why?
|
| Software | 4 | 2023 | 4463 | 0.400 |
Why?
|
| Inflammation | 18 | 2023 | 10865 | 0.400 |
Why?
|
| Lipids | 15 | 2024 | 3346 | 0.400 |
Why?
|
| Time Factors | 63 | 2024 | 40271 | 0.400 |
Why?
|
| Drug Prescriptions | 14 | 2018 | 1677 | 0.400 |
Why?
|
| Anti-Inflammatory Agents | 7 | 2020 | 1816 | 0.400 |
Why?
|
| Diabetic Retinopathy | 10 | 2023 | 1299 | 0.400 |
Why?
|
| Coronary Artery Disease | 8 | 2018 | 6551 | 0.390 |
Why?
|
| Data Collection | 7 | 2019 | 3329 | 0.390 |
Why?
|
| Drug Utilization | 15 | 2012 | 1192 | 0.390 |
Why?
|
| Glaucoma | 9 | 2023 | 1193 | 0.390 |
Why?
|
| Renal Insufficiency, Chronic | 5 | 2022 | 2291 | 0.390 |
Why?
|
| Databases, Factual | 17 | 2024 | 8081 | 0.390 |
Why?
|
| Matched-Pair Analysis | 5 | 2021 | 286 | 0.380 |
Why?
|
| Aging | 29 | 2015 | 8761 | 0.380 |
Why?
|
| Health Policy | 5 | 2018 | 2699 | 0.380 |
Why?
|
| Pennsylvania | 15 | 2013 | 616 | 0.380 |
Why?
|
| Alcohol Drinking | 26 | 2017 | 4052 | 0.380 |
Why?
|
| Cataract Extraction | 10 | 2016 | 465 | 0.380 |
Why?
|
| Age Factors | 42 | 2021 | 18478 | 0.380 |
Why?
|
| Cardiovascular Agents | 7 | 2018 | 849 | 0.370 |
Why?
|
| Lipoprotein(a) | 3 | 2024 | 488 | 0.370 |
Why?
|
| Smoking | 32 | 2021 | 9099 | 0.360 |
Why?
|
| Cyclooxygenase Inhibitors | 7 | 2017 | 361 | 0.350 |
Why?
|
| Prescription Fees | 4 | 2012 | 153 | 0.350 |
Why?
|
| Medication Adherence | 8 | 2023 | 2190 | 0.350 |
Why?
|
| Diastole | 7 | 2011 | 784 | 0.350 |
Why?
|
| Sulfonylurea Compounds | 4 | 2020 | 220 | 0.340 |
Why?
|
| Evidence-Based Medicine | 9 | 2021 | 3708 | 0.340 |
Why?
|
| Fibrinolytic Agents | 3 | 2009 | 2082 | 0.340 |
Why?
|
| Analgesics, Non-Narcotic | 4 | 2020 | 371 | 0.340 |
Why?
|
| Cognition | 7 | 2020 | 7066 | 0.340 |
Why?
|
| Inflammatory Bowel Diseases | 3 | 2022 | 2444 | 0.340 |
Why?
|
| Genetic Markers | 3 | 2020 | 2604 | 0.340 |
Why?
|
| Risk Adjustment | 5 | 2011 | 603 | 0.340 |
Why?
|
| Crohn Disease | 1 | 2022 | 2293 | 0.330 |
Why?
|
| Intercellular Adhesion Molecule-1 | 6 | 2016 | 1133 | 0.330 |
Why?
|
| Adrenergic beta-Antagonists | 9 | 2023 | 1244 | 0.330 |
Why?
|
| Odds Ratio | 34 | 2020 | 9687 | 0.330 |
Why?
|
| Hypertriglyceridemia | 2 | 2022 | 293 | 0.330 |
Why?
|
| European Union | 1 | 2010 | 157 | 0.330 |
Why?
|
| Analgesics, Opioid | 11 | 2024 | 3837 | 0.330 |
Why?
|
| Antipsychotic Agents | 11 | 2018 | 3077 | 0.320 |
Why?
|
| Monte Carlo Method | 7 | 2015 | 1262 | 0.320 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 13 | 2021 | 1518 | 0.320 |
Why?
|
| Colorectal Neoplasms | 9 | 2017 | 6978 | 0.320 |
Why?
|
| Linear Models | 15 | 2018 | 5880 | 0.320 |
Why?
|
| Hydroxychloroquine | 5 | 2024 | 427 | 0.320 |
Why?
|
| Case-Control Studies | 39 | 2024 | 22293 | 0.320 |
Why?
|
| Dyslipidemias | 5 | 2024 | 874 | 0.300 |
Why?
|
| Uveal Neoplasms | 12 | 1992 | 344 | 0.300 |
Why?
|
| Rhabdomyolysis | 4 | 2019 | 152 | 0.300 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 2 | 2007 | 425 | 0.290 |
Why?
|
| Imidazolidines | 3 | 2004 | 38 | 0.290 |
Why?
|
| Patient Admission | 6 | 2019 | 1370 | 0.290 |
Why?
|
| Gastrointestinal Hemorrhage | 7 | 2019 | 1126 | 0.290 |
Why?
|
| Ophthalmology | 3 | 2024 | 560 | 0.290 |
Why?
|
| Benzodiazepines | 7 | 2022 | 1139 | 0.290 |
Why?
|
| Secondary Prevention | 10 | 2018 | 1479 | 0.290 |
Why?
|
| Renal Dialysis | 6 | 2008 | 1802 | 0.290 |
Why?
|
| Visual Fields | 7 | 2017 | 1067 | 0.280 |
Why?
|
| Health Services Research | 6 | 2008 | 1815 | 0.280 |
Why?
|
| Drug Administration Schedule | 12 | 2018 | 4861 | 0.280 |
Why?
|
| Longitudinal Studies | 30 | 2021 | 14766 | 0.280 |
Why?
|
| Angina, Unstable | 6 | 2016 | 893 | 0.280 |
Why?
|
| Computer Security | 2 | 2019 | 260 | 0.280 |
Why?
|
| Hip Fractures | 6 | 2024 | 996 | 0.280 |
Why?
|
| Personnel, Hospital | 2 | 2019 | 285 | 0.280 |
Why?
|
| Hydrochlorothiazide | 5 | 2009 | 95 | 0.270 |
Why?
|
| Eicosapentaenoic Acid | 4 | 2022 | 563 | 0.270 |
Why?
|
| Lipoproteins, HDL | 3 | 2017 | 682 | 0.270 |
Why?
|
| Health Surveys | 9 | 2019 | 4056 | 0.270 |
Why?
|
| Vascular Diseases | 5 | 2019 | 1162 | 0.270 |
Why?
|
| Deductibles and Coinsurance | 5 | 2011 | 316 | 0.270 |
Why?
|
| Sex Factors | 20 | 2020 | 10647 | 0.270 |
Why?
|
| Triglycerides | 10 | 2022 | 2465 | 0.270 |
Why?
|
| Product Surveillance, Postmarketing | 4 | 2019 | 463 | 0.260 |
Why?
|
| Patient Selection | 8 | 2017 | 4266 | 0.260 |
Why?
|
| Drug Therapy, Combination | 12 | 2024 | 6320 | 0.260 |
Why?
|
| Thrombosis | 4 | 2020 | 2956 | 0.260 |
Why?
|
| Drug Utilization Review | 7 | 2007 | 248 | 0.260 |
Why?
|
| Biomedical Research | 3 | 2018 | 3463 | 0.250 |
Why?
|
| Fractures, Bone | 5 | 2024 | 2063 | 0.250 |
Why?
|
| Breast Neoplasms | 7 | 2022 | 21156 | 0.250 |
Why?
|
| Tramadol | 2 | 2024 | 63 | 0.250 |
Why?
|
| Recurrence | 12 | 2018 | 8510 | 0.250 |
Why?
|
| Drug Monitoring | 4 | 2017 | 964 | 0.240 |
Why?
|
| Body Mass Index | 20 | 2024 | 13030 | 0.240 |
Why?
|
| Activities of Daily Living | 7 | 2020 | 2433 | 0.240 |
Why?
|
| Chronic Disease | 10 | 2022 | 9382 | 0.240 |
Why?
|
| International Normalized Ratio | 6 | 2017 | 382 | 0.240 |
Why?
|
| Hospitalization | 28 | 2024 | 10845 | 0.240 |
Why?
|
| Injections, Subcutaneous | 4 | 2019 | 681 | 0.240 |
Why?
|
| Acetylglucosamine | 2 | 2016 | 189 | 0.240 |
Why?
|
| Cross-Over Studies | 6 | 2019 | 2103 | 0.240 |
Why?
|
| Calcium Channel Blockers | 3 | 2003 | 692 | 0.240 |
Why?
|
| Uric Acid | 6 | 2023 | 807 | 0.240 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 3 | 2011 | 246 | 0.230 |
Why?
|
| National Health Programs | 2 | 2009 | 442 | 0.230 |
Why?
|
| Mixed Function Oxygenases | 3 | 2011 | 265 | 0.230 |
Why?
|
| Nephrology | 3 | 2002 | 268 | 0.230 |
Why?
|
| Predictive Value of Tests | 30 | 2020 | 15460 | 0.230 |
Why?
|
| Antithrombins | 3 | 2019 | 294 | 0.230 |
Why?
|
| Lung Diseases, Obstructive | 1 | 2005 | 311 | 0.230 |
Why?
|
| Dose-Response Relationship, Drug | 18 | 2019 | 10784 | 0.230 |
Why?
|
| Baclofen | 2 | 2022 | 120 | 0.230 |
Why?
|
| Cholecalciferol | 2 | 2019 | 557 | 0.230 |
Why?
|
| Drug Interactions | 6 | 2021 | 1421 | 0.230 |
Why?
|
| Confidence Intervals | 15 | 2018 | 2932 | 0.230 |
Why?
|
| Drug Approval | 2 | 2011 | 817 | 0.220 |
Why?
|
| Gingival Diseases | 1 | 2004 | 37 | 0.220 |
Why?
|
| Practice Guidelines as Topic | 8 | 2018 | 7451 | 0.220 |
Why?
|
| Dihydropyridines | 1 | 2003 | 67 | 0.220 |
Why?
|
| Diabetes Mellitus, Type 1 | 7 | 2018 | 3440 | 0.220 |
Why?
|
| Periodontal Index | 1 | 2004 | 152 | 0.220 |
Why?
|
| Insurance Coverage | 6 | 2013 | 1946 | 0.220 |
Why?
|
| Cross-Sectional Studies | 27 | 2020 | 26351 | 0.220 |
Why?
|
| Public Health Informatics | 1 | 2004 | 109 | 0.210 |
Why?
|
| Depression | 8 | 2018 | 8235 | 0.210 |
Why?
|
| Anticonvulsants | 4 | 2015 | 1923 | 0.210 |
Why?
|
| Cholinergic Antagonists | 4 | 2009 | 167 | 0.210 |
Why?
|
| Vitamin B 12 | 3 | 2016 | 527 | 0.210 |
Why?
|
| Fibrinogen | 4 | 2016 | 892 | 0.210 |
Why?
|
| Diet | 6 | 2017 | 8098 | 0.210 |
Why?
|
| Kidney Failure, Chronic | 8 | 2003 | 2489 | 0.210 |
Why?
|
| Retrospective Studies | 60 | 2023 | 81834 | 0.210 |
Why?
|
| Patient Acceptance of Health Care | 5 | 2024 | 3237 | 0.210 |
Why?
|
| Carisoprodol | 1 | 2022 | 5 | 0.210 |
Why?
|
| Methocarbamol | 1 | 2022 | 8 | 0.210 |
Why?
|
| Dopamine Agonists | 1 | 2005 | 353 | 0.210 |
Why?
|
| Awareness | 1 | 2007 | 654 | 0.200 |
Why?
|
| Organoplatinum Compounds | 2 | 2015 | 408 | 0.200 |
Why?
|
| Diabetes Complications | 5 | 2018 | 1322 | 0.200 |
Why?
|
| Selection Bias | 4 | 2009 | 360 | 0.200 |
Why?
|
| Markov Chains | 4 | 2005 | 977 | 0.200 |
Why?
|
| Diabetes Mellitus | 10 | 2018 | 5887 | 0.200 |
Why?
|
| Polysaccharides | 3 | 2024 | 1024 | 0.200 |
Why?
|
| Fatty Acids, Omega-3 | 5 | 2024 | 1398 | 0.200 |
Why?
|
| Adrenergic beta-Agonists | 3 | 2009 | 347 | 0.200 |
Why?
|
| Health Services for the Aged | 2 | 2006 | 258 | 0.200 |
Why?
|
| Retinitis Pigmentosa | 3 | 2017 | 397 | 0.200 |
Why?
|
| Hepatitis | 1 | 2024 | 228 | 0.200 |
Why?
|
| Survival Analysis | 12 | 2023 | 10125 | 0.200 |
Why?
|
| Pyrazoles | 5 | 2024 | 2024 | 0.190 |
Why?
|
| Disorders of Excessive Somnolence | 1 | 2005 | 277 | 0.190 |
Why?
|
| Docosahexaenoic Acids | 3 | 2019 | 907 | 0.190 |
Why?
|
| Folic Acid | 4 | 2021 | 1336 | 0.190 |
Why?
|
| Kidney Diseases | 3 | 2008 | 2102 | 0.190 |
Why?
|
| Nutritional Status | 5 | 2018 | 1623 | 0.190 |
Why?
|
| Random Allocation | 4 | 2023 | 2399 | 0.190 |
Why?
|
| Osteoporotic Fractures | 2 | 2024 | 417 | 0.190 |
Why?
|
| Polyglutamic Acid | 1 | 2021 | 47 | 0.190 |
Why?
|
| Self Care | 1 | 2007 | 798 | 0.190 |
Why?
|
| Valine | 3 | 2008 | 410 | 0.190 |
Why?
|
| Tetanus | 1 | 2021 | 52 | 0.190 |
Why?
|
| Diphtheria | 1 | 2021 | 32 | 0.190 |
Why?
|
| Socioeconomic Factors | 12 | 2024 | 7863 | 0.190 |
Why?
|
| Neoplasms | 24 | 2019 | 22386 | 0.190 |
Why?
|
| PPAR alpha | 1 | 2022 | 177 | 0.190 |
Why?
|
| Gastrointestinal Diseases | 3 | 2008 | 1207 | 0.190 |
Why?
|
| Apolipoproteins B | 3 | 2021 | 386 | 0.190 |
Why?
|
| ROC Curve | 6 | 2021 | 3624 | 0.180 |
Why?
|
| Ventricular Dysfunction, Left | 4 | 2023 | 2145 | 0.180 |
Why?
|
| Phospholipids | 3 | 2014 | 783 | 0.180 |
Why?
|
| Ticlopidine | 2 | 2017 | 730 | 0.180 |
Why?
|
| Health Status Indicators | 4 | 2019 | 971 | 0.180 |
Why?
|
| Whooping Cough | 1 | 2021 | 86 | 0.180 |
Why?
|
| Arteritis | 1 | 2022 | 158 | 0.180 |
Why?
|
| Life Expectancy | 3 | 2024 | 1249 | 0.180 |
Why?
|
| Health Services Accessibility | 5 | 2020 | 5510 | 0.180 |
Why?
|
| Neuromuscular Agents | 1 | 2022 | 148 | 0.180 |
Why?
|
| Vitamin B Complex | 2 | 2016 | 299 | 0.180 |
Why?
|
| Electronic Mail | 2 | 2019 | 215 | 0.180 |
Why?
|
| Lorazepam | 1 | 2021 | 155 | 0.180 |
Why?
|
| Geriatrics | 1 | 2005 | 390 | 0.180 |
Why?
|
| Receptors, Progesterone | 2 | 2017 | 1145 | 0.180 |
Why?
|
| Myocardial Revascularization | 5 | 2016 | 796 | 0.180 |
Why?
|
| Models, Theoretical | 4 | 2008 | 3590 | 0.180 |
Why?
|
| Calibration | 4 | 2020 | 823 | 0.170 |
Why?
|
| Drug Dosage Calculations | 2 | 2011 | 117 | 0.170 |
Why?
|
| Spironolactone | 1 | 2024 | 412 | 0.170 |
Why?
|
| Nurses | 7 | 2017 | 2494 | 0.170 |
Why?
|
| Costs and Cost Analysis | 4 | 2009 | 1670 | 0.170 |
Why?
|
| Drug Therapy | 2 | 2001 | 504 | 0.170 |
Why?
|
| Vision Disorders | 5 | 2012 | 1092 | 0.170 |
Why?
|
| Plaque, Atherosclerotic | 2 | 2016 | 1547 | 0.170 |
Why?
|
| Reproducibility of Results | 17 | 2019 | 20231 | 0.170 |
Why?
|
| Pyridones | 3 | 2024 | 819 | 0.170 |
Why?
|
| Self Disclosure | 6 | 2005 | 249 | 0.170 |
Why?
|
| Ophthalmoscopy | 1 | 2020 | 172 | 0.170 |
Why?
|
| Polymorphism, Genetic | 6 | 2011 | 4249 | 0.170 |
Why?
|
| Vitamin B 6 | 2 | 2016 | 234 | 0.170 |
Why?
|
| Sodium | 5 | 2022 | 1595 | 0.170 |
Why?
|
| Lipoproteins, VLDL | 2 | 2017 | 201 | 0.170 |
Why?
|
| Restless Legs Syndrome | 2 | 2013 | 235 | 0.170 |
Why?
|
| Group II Phospholipases A2 | 1 | 2019 | 12 | 0.170 |
Why?
|
| Polymorphism, Single Nucleotide | 6 | 2019 | 16029 | 0.170 |
Why?
|
| tau Proteins | 2 | 2020 | 2129 | 0.170 |
Why?
|
| Continuity of Patient Care | 3 | 2021 | 1076 | 0.160 |
Why?
|
| Diabetic Nephropathies | 3 | 2018 | 975 | 0.160 |
Why?
|
| Glaucoma, Open-Angle | 4 | 2000 | 742 | 0.160 |
Why?
|
| Analgesics | 4 | 2017 | 1070 | 0.160 |
Why?
|
| Health Services | 5 | 2010 | 756 | 0.160 |
Why?
|
| Area Under Curve | 4 | 2021 | 1640 | 0.160 |
Why?
|
| Fluorouracil | 2 | 2015 | 1656 | 0.160 |
Why?
|
| Trabeculectomy | 2 | 1993 | 174 | 0.160 |
Why?
|
| Kidney Transplantation | 4 | 2008 | 4285 | 0.160 |
Why?
|
| Optic Neuritis | 1 | 2021 | 175 | 0.160 |
Why?
|
| Statistics as Topic | 4 | 2011 | 2362 | 0.160 |
Why?
|
| Diabetic Neuropathies | 2 | 2018 | 411 | 0.160 |
Why?
|
| Medically Uninsured | 3 | 2013 | 841 | 0.160 |
Why?
|
| Glycoproteins | 2 | 2016 | 2206 | 0.150 |
Why?
|
| Melanoma | 13 | 2022 | 5740 | 0.150 |
Why?
|
| Thalidomide | 1 | 2024 | 885 | 0.150 |
Why?
|
| Stapes Surgery | 2 | 2001 | 60 | 0.150 |
Why?
|
| Lens Capsule, Crystalline | 1 | 1998 | 38 | 0.150 |
Why?
|
| Treatment Refusal | 3 | 1998 | 432 | 0.150 |
Why?
|
| Simvastatin | 2 | 2012 | 346 | 0.150 |
Why?
|
| Vestibular Nerve | 4 | 2000 | 101 | 0.150 |
Why?
|
| Genetic Predisposition to Disease | 9 | 2019 | 18048 | 0.150 |
Why?
|
| Polyradiculoneuropathy, Chronic Inflammatory Demyelinating | 1 | 2018 | 37 | 0.150 |
Why?
|
| Hand Joints | 1 | 2018 | 58 | 0.150 |
Why?
|
| Disease Progression | 12 | 2020 | 13655 | 0.150 |
Why?
|
| Inappropriate Prescribing | 1 | 2021 | 212 | 0.150 |
Why?
|
| Glucose | 7 | 2022 | 4355 | 0.150 |
Why?
|
| Body Size | 2 | 2015 | 463 | 0.150 |
Why?
|
| Carcinoma, Basal Cell | 2 | 2022 | 564 | 0.150 |
Why?
|
| Angioedema | 1 | 2019 | 184 | 0.150 |
Why?
|
| Blood Coagulation | 2 | 2017 | 1162 | 0.150 |
Why?
|
| Psychotic Disorders | 3 | 2024 | 3278 | 0.150 |
Why?
|
| Health Personnel | 10 | 2024 | 3384 | 0.150 |
Why?
|
| Milk, Human | 1 | 2022 | 489 | 0.150 |
Why?
|
| Butyrates | 1 | 2018 | 168 | 0.150 |
Why?
|
| Age Distribution | 8 | 2020 | 2881 | 0.150 |
Why?
|
| Community Pharmacy Services | 1 | 2018 | 52 | 0.150 |
Why?
|
| Benzoxazoles | 1 | 2018 | 92 | 0.150 |
Why?
|
| Cardiology Service, Hospital | 1 | 2019 | 241 | 0.150 |
Why?
|
| Placebos | 7 | 2020 | 1668 | 0.140 |
Why?
|
| Prognosis | 18 | 2022 | 30028 | 0.140 |
Why?
|
| Homocysteine | 4 | 2022 | 637 | 0.140 |
Why?
|
| Selenium | 1 | 2020 | 419 | 0.140 |
Why?
|
| Angioplasty | 2 | 2010 | 357 | 0.140 |
Why?
|
| Staff Development | 1 | 2019 | 230 | 0.140 |
Why?
|
| Tetrazoles | 3 | 2008 | 922 | 0.140 |
Why?
|
| Hemangiosarcoma | 1 | 2019 | 216 | 0.140 |
Why?
|
| Medical Records | 4 | 2018 | 1413 | 0.140 |
Why?
|
| Peptic Ulcer | 2 | 2009 | 222 | 0.140 |
Why?
|
| Gestational Age | 3 | 2020 | 3615 | 0.140 |
Why?
|
| Signal Transduction | 2 | 2018 | 23638 | 0.140 |
Why?
|
| Mental Status Schedule | 2 | 1999 | 315 | 0.140 |
Why?
|
| Quality Assurance, Health Care | 1 | 2007 | 2179 | 0.140 |
Why?
|
| Bone Density Conservation Agents | 1 | 2024 | 797 | 0.140 |
Why?
|
| Receptors, Estrogen | 2 | 2017 | 2243 | 0.140 |
Why?
|
| Peritoneal Dialysis | 3 | 2002 | 160 | 0.140 |
Why?
|
| Decision Support Techniques | 4 | 2017 | 2010 | 0.140 |
Why?
|
| Pravastatin | 5 | 2006 | 393 | 0.140 |
Why?
|
| Disease Management | 2 | 2018 | 2533 | 0.140 |
Why?
|
| Medication Therapy Management | 1 | 2018 | 131 | 0.140 |
Why?
|
| Immunosuppressive Agents | 2 | 2020 | 4213 | 0.130 |
Why?
|
| Hospital Information Systems | 1 | 2019 | 394 | 0.130 |
Why?
|
| Anemia | 2 | 2020 | 1521 | 0.130 |
Why?
|
| Lens Implantation, Intraocular | 1 | 1998 | 192 | 0.130 |
Why?
|
| Laser Therapy | 3 | 1997 | 1107 | 0.130 |
Why?
|
| Haloperidol | 1 | 2018 | 394 | 0.130 |
Why?
|
| Respiratory Tract Infections | 1 | 2024 | 1013 | 0.130 |
Why?
|
| Acetylgalactosamine | 1 | 2016 | 41 | 0.130 |
Why?
|
| Child | 17 | 2023 | 80863 | 0.130 |
Why?
|
| Models, Cardiovascular | 1 | 2002 | 986 | 0.130 |
Why?
|
| Colonic Neoplasms | 3 | 2015 | 2544 | 0.130 |
Why?
|
| Brain Ischemia | 6 | 2013 | 3038 | 0.130 |
Why?
|
| Hair Cells, Vestibular | 3 | 2000 | 50 | 0.130 |
Why?
|
| Dementia | 2 | 2022 | 2723 | 0.130 |
Why?
|
| Adolescent | 34 | 2024 | 89168 | 0.130 |
Why?
|
| Azithromycin | 2 | 2019 | 200 | 0.130 |
Why?
|
| Infant, Premature | 2 | 2022 | 2124 | 0.130 |
Why?
|
| Amino Acid Metabolism, Inborn Errors | 1 | 2018 | 284 | 0.130 |
Why?
|
| Retinopathy of Prematurity | 1 | 2020 | 449 | 0.120 |
Why?
|
| Hypotension | 2 | 2002 | 888 | 0.120 |
Why?
|
| Risk Management | 1 | 2019 | 558 | 0.120 |
Why?
|
| Benzothiadiazines | 5 | 2001 | 31 | 0.120 |
Why?
|
| Insurance Claim Reporting | 3 | 2007 | 166 | 0.120 |
Why?
|
| Selenomethionine | 1 | 2015 | 18 | 0.120 |
Why?
|
| Incretins | 1 | 2016 | 100 | 0.120 |
Why?
|
| Pharmaceutical Preparations | 2 | 2021 | 1089 | 0.120 |
Why?
|
| Death, Sudden, Cardiac | 2 | 2017 | 1568 | 0.120 |
Why?
|
| Cochlea | 3 | 1990 | 846 | 0.120 |
Why?
|
| Prejudice | 2 | 2010 | 574 | 0.120 |
Why?
|
| Clinical Trials as Topic | 6 | 2015 | 8051 | 0.120 |
Why?
|
| Refractive Errors | 1 | 2017 | 148 | 0.120 |
Why?
|
| Fatty Acids, Omega-6 | 2 | 2015 | 225 | 0.120 |
Why?
|
| Pneumonia | 2 | 2020 | 2162 | 0.120 |
Why?
|
| Factor V | 3 | 2009 | 168 | 0.120 |
Why?
|
| Nitric Oxide Synthase Type III | 2 | 2008 | 706 | 0.120 |
Why?
|
| Telemedicine | 2 | 2024 | 3104 | 0.120 |
Why?
|
| Spiral Ganglion | 4 | 2000 | 177 | 0.120 |
Why?
|
| Xanthine Oxidase | 1 | 2015 | 69 | 0.120 |
Why?
|
| Diuretics | 8 | 2009 | 612 | 0.120 |
Why?
|
| Administration, Oral | 7 | 2024 | 4041 | 0.120 |
Why?
|
| Lactones | 2 | 2009 | 316 | 0.120 |
Why?
|
| Sodium Chloride Symporter Inhibitors | 5 | 2001 | 78 | 0.120 |
Why?
|
| Clinical Medicine | 1 | 1996 | 145 | 0.120 |
Why?
|
| Smoking Cessation | 3 | 2016 | 2079 | 0.120 |
Why?
|
| Hearing Loss, Sensorineural | 4 | 2001 | 783 | 0.120 |
Why?
|
| Radiation Injuries | 3 | 2019 | 1205 | 0.120 |
Why?
|
| Massachusetts | 16 | 2021 | 8908 | 0.110 |
Why?
|
| Vision Tests | 2 | 1994 | 160 | 0.110 |
Why?
|
| Laurence-Moon Syndrome | 1 | 1993 | 9 | 0.110 |
Why?
|
| Bariatric Surgery | 1 | 2024 | 1007 | 0.110 |
Why?
|
| Hospital Mortality | 6 | 2018 | 5371 | 0.110 |
Why?
|
| Substance-Related Disorders | 3 | 2022 | 4453 | 0.110 |
Why?
|
| Health Expenditures | 8 | 2012 | 2391 | 0.110 |
Why?
|
| Atrial Natriuretic Factor | 2 | 2007 | 350 | 0.110 |
Why?
|
| Tissue Survival | 1 | 2014 | 120 | 0.110 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2019 | 4049 | 0.110 |
Why?
|
| Kidney | 7 | 2021 | 7064 | 0.110 |
Why?
|
| Boston | 15 | 2019 | 9361 | 0.110 |
Why?
|
| Coronary Artery Bypass | 3 | 2013 | 2194 | 0.110 |
Why?
|
| Canada | 3 | 2010 | 2143 | 0.110 |
Why?
|
| Immunoglobulins | 1 | 2017 | 856 | 0.110 |
Why?
|
| Cognition Disorders | 5 | 2013 | 3985 | 0.110 |
Why?
|
| Endpoint Determination | 5 | 2018 | 591 | 0.110 |
Why?
|
| Thiazoles | 2 | 2018 | 1541 | 0.110 |
Why?
|
| Temporal Bone | 3 | 1999 | 683 | 0.110 |
Why?
|
| Renin-Angiotensin System | 2 | 2008 | 735 | 0.110 |
Why?
|
| Renal Insufficiency | 3 | 2005 | 809 | 0.110 |
Why?
|
| Autoimmune Diseases | 2 | 2017 | 2260 | 0.110 |
Why?
|
| Sarcopenia | 1 | 2018 | 376 | 0.110 |
Why?
|
| alpha-Linolenic Acid | 1 | 2014 | 144 | 0.110 |
Why?
|
| Quality Indicators, Health Care | 3 | 2017 | 1813 | 0.110 |
Why?
|
| Severity of Illness Index | 12 | 2023 | 15965 | 0.110 |
Why?
|
| Hematuria | 1 | 2014 | 233 | 0.110 |
Why?
|
| Gout Suppressants | 1 | 2015 | 177 | 0.110 |
Why?
|
| Evaluation Studies as Topic | 7 | 2008 | 1629 | 0.110 |
Why?
|
| Peptide Fragments | 2 | 2020 | 5152 | 0.110 |
Why?
|
| United States Food and Drug Administration | 2 | 2019 | 1669 | 0.110 |
Why?
|
| Healthcare Disparities | 3 | 2021 | 3412 | 0.110 |
Why?
|
| Retina | 2 | 2021 | 2663 | 0.100 |
Why?
|
| Vulnerable Populations | 1 | 2018 | 717 | 0.100 |
Why?
|
| Risk Reduction Behavior | 2 | 2011 | 1120 | 0.100 |
Why?
|
| Employment | 2 | 2012 | 1120 | 0.100 |
Why?
|
| Morbidity | 3 | 2017 | 1760 | 0.100 |
Why?
|
| Pharmacogenetics | 2 | 2008 | 677 | 0.100 |
Why?
|
| Ketolides | 1 | 2012 | 12 | 0.100 |
Why?
|
| Financing, Personal | 2 | 2012 | 310 | 0.100 |
Why?
|
| Inflammation Mediators | 3 | 2019 | 1892 | 0.100 |
Why?
|
| Decision Making | 3 | 2019 | 3961 | 0.100 |
Why?
|
| Information Storage and Retrieval | 1 | 2018 | 823 | 0.100 |
Why?
|
| Steroids | 2 | 2009 | 937 | 0.100 |
Why?
|
| Angiotensin Receptor Antagonists | 2 | 2023 | 1066 | 0.100 |
Why?
|
| Academic Medical Centers | 2 | 2020 | 2785 | 0.100 |
Why?
|
| Sensitivity and Specificity | 13 | 2020 | 14728 | 0.100 |
Why?
|
| Skin Neoplasms | 4 | 2022 | 5891 | 0.100 |
Why?
|
| Glomerular Filtration Rate | 7 | 2021 | 2226 | 0.100 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 4 | 2008 | 429 | 0.100 |
Why?
|
| Patient Discharge | 3 | 2008 | 3471 | 0.100 |
Why?
|
| Geographic Atrophy | 1 | 2013 | 92 | 0.100 |
Why?
|
| Abnormalities, Drug-Induced | 1 | 2015 | 341 | 0.100 |
Why?
|
| Antibodies | 2 | 2017 | 2425 | 0.100 |
Why?
|
| Poisson Distribution | 4 | 2012 | 509 | 0.100 |
Why?
|
| Diet Surveys | 3 | 2011 | 1161 | 0.100 |
Why?
|
| Alzheimer Disease | 4 | 2020 | 8721 | 0.100 |
Why?
|
| Vision, Low | 1 | 1994 | 163 | 0.100 |
Why?
|
| Alcoholism | 6 | 2005 | 1993 | 0.100 |
Why?
|
| Survival Rate | 10 | 2017 | 12875 | 0.100 |
Why?
|
| Registries | 8 | 2015 | 8373 | 0.100 |
Why?
|
| Trans Fatty Acids | 1 | 2013 | 155 | 0.100 |
Why?
|
| Blood Glucose | 3 | 2018 | 6429 | 0.100 |
Why?
|
| Inpatients | 2 | 2020 | 2561 | 0.100 |
Why?
|
| Pyridines | 3 | 2017 | 2888 | 0.100 |
Why?
|
| Clozapine | 3 | 2005 | 508 | 0.100 |
Why?
|
| Down Syndrome | 1 | 2020 | 914 | 0.100 |
Why?
|
| Bayes Theorem | 3 | 2021 | 2358 | 0.100 |
Why?
|
| Prothrombin | 3 | 2009 | 192 | 0.100 |
Why?
|
| Azetidines | 1 | 2012 | 143 | 0.100 |
Why?
|
| Carotenoids | 4 | 2008 | 621 | 0.090 |
Why?
|
| False Positive Reactions | 2 | 2012 | 962 | 0.090 |
Why?
|
| Health Behavior | 4 | 2011 | 2649 | 0.090 |
Why?
|
| Data Mining | 2 | 2018 | 561 | 0.090 |
Why?
|
| Medicaid | 13 | 2021 | 2843 | 0.090 |
Why?
|
| Prenatal Exposure Delayed Effects | 2 | 2015 | 2538 | 0.090 |
Why?
|
| Schizophrenia | 3 | 2024 | 6986 | 0.090 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 2 | 2012 | 495 | 0.090 |
Why?
|
| Social Class | 4 | 2021 | 2000 | 0.090 |
Why?
|
| Corneal Ulcer | 3 | 1991 | 127 | 0.090 |
Why?
|
| Insulin | 3 | 2016 | 6606 | 0.090 |
Why?
|
| Evoked Potentials, Auditory, Brain Stem | 1 | 1992 | 255 | 0.090 |
Why?
|
| Parkinson Disease | 1 | 2005 | 2891 | 0.090 |
Why?
|
| Drug Evaluation | 1 | 2012 | 642 | 0.090 |
Why?
|
| Hyperlipoproteinemia Type II | 1 | 2016 | 398 | 0.090 |
Why?
|
| Body Constitution | 4 | 2000 | 273 | 0.090 |
Why?
|
| Natriuretic Peptide, Brain | 2 | 2015 | 1751 | 0.090 |
Why?
|
| Tuberculosis | 1 | 2024 | 2030 | 0.090 |
Why?
|
| Cyclohexanecarboxylic Acids | 1 | 2011 | 140 | 0.090 |
Why?
|
| Labyrinthitis | 1 | 1990 | 32 | 0.090 |
Why?
|
| Memory Disorders | 1 | 2018 | 1204 | 0.090 |
Why?
|
| Wet Macular Degeneration | 1 | 2013 | 165 | 0.090 |
Why?
|
| Ramipril | 3 | 2001 | 102 | 0.090 |
Why?
|
| International Classification of Diseases | 3 | 2011 | 925 | 0.090 |
Why?
|
| Aphakia, Postcataract | 1 | 1991 | 52 | 0.090 |
Why?
|
| Coronary Stenosis | 1 | 2016 | 803 | 0.090 |
Why?
|
| Fatty Acids, Unsaturated | 1 | 2014 | 542 | 0.090 |
Why?
|
| Referral and Consultation | 5 | 2012 | 3629 | 0.090 |
Why?
|
| Prescriptions | 2 | 2024 | 387 | 0.090 |
Why?
|
| Accidental Falls | 3 | 2018 | 1081 | 0.090 |
Why?
|
| Sepsis | 2 | 2022 | 2602 | 0.090 |
Why?
|
| Tumor Necrosis Factor-alpha | 4 | 2024 | 4362 | 0.090 |
Why?
|
| Carcinoma, Squamous Cell | 3 | 2022 | 4083 | 0.090 |
Why?
|
| Antiparkinson Agents | 2 | 2005 | 184 | 0.090 |
Why?
|
| Vitamin D | 1 | 2024 | 3311 | 0.090 |
Why?
|
| Fructose | 1 | 2012 | 285 | 0.090 |
Why?
|
| Retirement | 3 | 1989 | 198 | 0.090 |
Why?
|
| Exercise | 7 | 2018 | 5940 | 0.090 |
Why?
|
| Drug Combinations | 5 | 2016 | 2079 | 0.090 |
Why?
|
| Hemoglobins | 2 | 2020 | 1532 | 0.090 |
Why?
|
| Uterine Cervical Dysplasia | 1 | 2014 | 387 | 0.090 |
Why?
|
| Amines | 1 | 2011 | 280 | 0.090 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 1 | 2014 | 450 | 0.090 |
Why?
|
| Hypnotics and Sedatives | 4 | 2021 | 1188 | 0.090 |
Why?
|
| Troponin T | 1 | 2015 | 787 | 0.090 |
Why?
|
| Off-Label Use | 1 | 2011 | 186 | 0.080 |
Why?
|
| Safety-Based Drug Withdrawals | 1 | 2009 | 36 | 0.080 |
Why?
|
| Abortion, Spontaneous | 1 | 2015 | 539 | 0.080 |
Why?
|
| Rheumatic Diseases | 1 | 2017 | 664 | 0.080 |
Why?
|
| Biological Products | 1 | 2019 | 937 | 0.080 |
Why?
|
| New England | 7 | 1993 | 1056 | 0.080 |
Why?
|
| Cost of Illness | 2 | 2018 | 1960 | 0.080 |
Why?
|
| Health Care Costs | 6 | 2024 | 3265 | 0.080 |
Why?
|
| Marketing | 1 | 2011 | 224 | 0.080 |
Why?
|
| Insurance, Health | 2 | 2021 | 2513 | 0.080 |
Why?
|
| Models, Biological | 3 | 2018 | 9505 | 0.080 |
Why?
|
| Tobacco Smoke Pollution | 1 | 2015 | 828 | 0.080 |
Why?
|
| Peptidyl-Dipeptidase A | 2 | 2008 | 330 | 0.080 |
Why?
|
| Anti-Ulcer Agents | 2 | 2009 | 112 | 0.080 |
Why?
|
| Stapes | 2 | 2001 | 89 | 0.080 |
Why?
|
| Retinal Degeneration | 1 | 1993 | 415 | 0.080 |
Why?
|
| Contact Lenses | 1 | 1991 | 138 | 0.080 |
Why?
|
| Sulfones | 2 | 2009 | 448 | 0.080 |
Why?
|
| Epidemiologic Measurements | 1 | 2009 | 23 | 0.080 |
Why?
|
| Fees, Pharmaceutical | 1 | 2009 | 66 | 0.080 |
Why?
|
| Skin | 3 | 2019 | 4520 | 0.080 |
Why?
|
| Prevalence | 13 | 2024 | 15880 | 0.080 |
Why?
|
| Forecasting | 5 | 2013 | 2950 | 0.080 |
Why?
|
| Deafness | 2 | 1993 | 462 | 0.080 |
Why?
|
| Bone Neoplasms | 2 | 2001 | 2562 | 0.080 |
Why?
|
| Thiophenes | 1 | 2013 | 570 | 0.080 |
Why?
|
| Otosclerosis | 2 | 2001 | 113 | 0.080 |
Why?
|
| Heart Diseases | 4 | 2015 | 2816 | 0.080 |
Why?
|
| Vaccination | 1 | 2021 | 3434 | 0.080 |
Why?
|
| Phenotype | 3 | 2018 | 16712 | 0.080 |
Why?
|
| Digoxin | 2 | 2004 | 246 | 0.080 |
Why?
|
| Cytochrome P-450 CYP3A | 2 | 2019 | 118 | 0.080 |
Why?
|
| Pyridoxine | 1 | 2009 | 109 | 0.080 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 2 | 2008 | 692 | 0.080 |
Why?
|
| Oval Window, Ear | 2 | 1999 | 21 | 0.080 |
Why?
|
| Fatty Acids | 2 | 2015 | 1818 | 0.080 |
Why?
|
| Medical Assistance | 2 | 2012 | 108 | 0.080 |
Why?
|
| Neuroma, Acoustic | 1 | 1992 | 458 | 0.080 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2014 | 1142 | 0.080 |
Why?
|
| Cochlear Nerve | 1 | 1990 | 202 | 0.080 |
Why?
|
| Myocardial Contraction | 1 | 2014 | 1527 | 0.080 |
Why?
|
| Drug Industry | 2 | 2012 | 793 | 0.080 |
Why?
|
| Immunologic Factors | 3 | 2024 | 1600 | 0.080 |
Why?
|
| Type A Personality | 1 | 1988 | 24 | 0.080 |
Why?
|
| Facial Paralysis | 1 | 1992 | 346 | 0.080 |
Why?
|
| Intracranial Hemorrhages | 2 | 2012 | 815 | 0.080 |
Why?
|
| Hypertension, Renal | 1 | 2008 | 135 | 0.080 |
Why?
|
| Attitude of Health Personnel | 1 | 2002 | 3922 | 0.080 |
Why?
|
| Pain | 3 | 2017 | 5096 | 0.080 |
Why?
|
| Diabetes, Gestational | 1 | 2018 | 1259 | 0.080 |
Why?
|
| Research Support as Topic | 1 | 2012 | 699 | 0.070 |
Why?
|
| Neutrophils | 1 | 2021 | 3790 | 0.070 |
Why?
|
| Accidents | 1 | 2009 | 165 | 0.070 |
Why?
|
| Least-Squares Analysis | 1 | 2008 | 368 | 0.070 |
Why?
|
| Eating | 2 | 2022 | 1538 | 0.070 |
Why?
|
| Epidemiologic Factors | 1 | 2007 | 36 | 0.070 |
Why?
|
| Neurofilament Proteins | 2 | 2020 | 337 | 0.070 |
Why?
|
| Glucagon-Like Peptide 1 | 2 | 2021 | 367 | 0.070 |
Why?
|
| Activated Protein C Resistance | 1 | 2007 | 18 | 0.070 |
Why?
|
| Body Weight | 7 | 2017 | 4630 | 0.070 |
Why?
|
| Hydrocodone | 2 | 2022 | 48 | 0.070 |
Why?
|
| Seafood | 1 | 2011 | 395 | 0.070 |
Why?
|
| Tinnitus | 1 | 1990 | 197 | 0.070 |
Why?
|
| Analysis of Variance | 9 | 2011 | 6242 | 0.070 |
Why?
|
| Tomography, Optical Coherence | 1 | 2021 | 2958 | 0.070 |
Why?
|
| Medical Record Linkage | 2 | 2007 | 286 | 0.070 |
Why?
|
| Self Medication | 2 | 2006 | 117 | 0.070 |
Why?
|
| Education, Medical, Continuing | 2 | 2024 | 829 | 0.070 |
Why?
|
| Management Information Systems | 1 | 2007 | 49 | 0.070 |
Why?
|
| Research | 1 | 1996 | 1984 | 0.070 |
Why?
|
| Alcoholic Intoxication | 2 | 1985 | 176 | 0.070 |
Why?
|
| Control Groups | 1 | 2007 | 107 | 0.070 |
Why?
|
| Pregnancy | 8 | 2021 | 30179 | 0.070 |
Why?
|
| Kaplan-Meier Estimate | 6 | 2016 | 6537 | 0.070 |
Why?
|
| Health | 1 | 2010 | 399 | 0.070 |
Why?
|
| Preventive Medicine | 1 | 2009 | 245 | 0.070 |
Why?
|
| Vision Screening | 3 | 2000 | 72 | 0.070 |
Why?
|
| Dietary Fats | 1 | 2015 | 2003 | 0.070 |
Why?
|
| Program Evaluation | 3 | 2019 | 2508 | 0.070 |
Why?
|
| Body Height | 4 | 2000 | 1568 | 0.070 |
Why?
|
| Adiponectin | 1 | 2013 | 1118 | 0.070 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2017 | 2258 | 0.070 |
Why?
|
| Piperazines | 2 | 2018 | 2546 | 0.070 |
Why?
|
| Bone Density | 2 | 2017 | 3561 | 0.070 |
Why?
|
| Osteoporosis | 2 | 2007 | 1606 | 0.070 |
Why?
|
| Intraocular Pressure | 4 | 2007 | 1304 | 0.070 |
Why?
|
| Epistasis, Genetic | 1 | 2009 | 352 | 0.070 |
Why?
|
| Overweight | 2 | 2009 | 2428 | 0.070 |
Why?
|
| Menopause | 1 | 2015 | 1651 | 0.070 |
Why?
|
| Cleft Lip | 1 | 2012 | 513 | 0.070 |
Why?
|
| Pregnancy Complications | 2 | 2018 | 2969 | 0.070 |
Why?
|
| Heart Atria | 1 | 2013 | 1361 | 0.070 |
Why?
|
| Insulin Resistance | 2 | 2021 | 3974 | 0.070 |
Why?
|
| Amyloid beta-Peptides | 1 | 2020 | 3891 | 0.070 |
Why?
|
| Cleft Palate | 1 | 2012 | 598 | 0.070 |
Why?
|
| Influenza Vaccines | 1 | 2014 | 781 | 0.070 |
Why?
|
| Life Style | 4 | 2014 | 3929 | 0.070 |
Why?
|
| Patient-Centered Care | 1 | 2016 | 1439 | 0.070 |
Why?
|
| Drug Design | 1 | 2011 | 1050 | 0.070 |
Why?
|
| Multicenter Studies as Topic | 4 | 2007 | 1727 | 0.070 |
Why?
|
| Obesity | 6 | 2024 | 13065 | 0.070 |
Why?
|
| Contact Lenses, Extended-Wear | 3 | 1991 | 12 | 0.070 |
Why?
|
| Oxycodone | 2 | 2022 | 142 | 0.070 |
Why?
|
| Stroke Volume | 7 | 2024 | 5620 | 0.070 |
Why?
|
| Young Adult | 13 | 2024 | 60045 | 0.070 |
Why?
|
| Echocardiography | 4 | 2014 | 5043 | 0.070 |
Why?
|
| Functional Laterality | 1 | 1993 | 2268 | 0.070 |
Why?
|
| Direct Service Costs | 2 | 2002 | 61 | 0.070 |
Why?
|
| Leisure Activities | 1 | 2007 | 310 | 0.060 |
Why?
|
| Monitoring, Intraoperative | 1 | 1992 | 952 | 0.060 |
Why?
|
| Income | 5 | 2011 | 1878 | 0.060 |
Why?
|
| 1-Alkyl-2-acetylglycerophosphocholine Esterase | 2 | 2022 | 127 | 0.060 |
Why?
|
| Liver Diseases | 1 | 2014 | 1307 | 0.060 |
Why?
|
| Chi-Square Distribution | 4 | 2016 | 3438 | 0.060 |
Why?
|
| Contact Lenses, Hydrophilic | 3 | 1991 | 53 | 0.060 |
Why?
|
| Genotype | 6 | 2011 | 13047 | 0.060 |
Why?
|
| Therapeutics | 1 | 2006 | 113 | 0.060 |
Why?
|
| Omeprazole | 1 | 2006 | 106 | 0.060 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2017 | 1644 | 0.060 |
Why?
|
| Palliative Care | 2 | 2012 | 3644 | 0.060 |
Why?
|
| Diet Records | 1 | 2007 | 427 | 0.060 |
Why?
|
| Tissue Plasminogen Activator | 2 | 2005 | 1166 | 0.060 |
Why?
|
| Endometrial Neoplasms | 1 | 2015 | 1382 | 0.060 |
Why?
|
| Medication Systems | 1 | 2005 | 31 | 0.060 |
Why?
|
| 3' Untranslated Regions | 1 | 2007 | 515 | 0.060 |
Why?
|
| gamma-Aminobutyric Acid | 1 | 2011 | 1140 | 0.060 |
Why?
|
| Infant, Newborn | 8 | 2022 | 26395 | 0.060 |
Why?
|
| Eye Injuries | 1 | 1988 | 228 | 0.060 |
Why?
|
| Acute-Phase Proteins | 2 | 2016 | 251 | 0.060 |
Why?
|
| Diagnosis-Related Groups | 2 | 2004 | 448 | 0.060 |
Why?
|
| Hearing Loss | 1 | 1992 | 786 | 0.060 |
Why?
|
| Gene Frequency | 2 | 2009 | 3615 | 0.060 |
Why?
|
| Infant | 10 | 2022 | 36497 | 0.060 |
Why?
|
| Glucocorticoids | 3 | 2008 | 2170 | 0.060 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 2014 | 1097 | 0.060 |
Why?
|
| Phospholipases A | 1 | 2005 | 204 | 0.060 |
Why?
|
| Quality-Adjusted Life Years | 4 | 2024 | 1734 | 0.060 |
Why?
|
| Prostatic Diseases | 1 | 1985 | 57 | 0.060 |
Why?
|
| Thrombophilia | 1 | 2007 | 306 | 0.060 |
Why?
|
| Creatinine | 7 | 2005 | 1915 | 0.060 |
Why?
|
| Respiratory Tract Diseases | 1 | 2010 | 749 | 0.060 |
Why?
|
| Lupus Erythematosus, Systemic | 2 | 2014 | 2173 | 0.060 |
Why?
|
| Virus Diseases | 1 | 1990 | 723 | 0.060 |
Why?
|
| Serum Albumin | 1 | 1988 | 676 | 0.060 |
Why?
|
| Guideline Adherence | 4 | 2013 | 2239 | 0.060 |
Why?
|
| Dental Calculus | 1 | 2004 | 12 | 0.060 |
Why?
|
| Educational Status | 5 | 2011 | 2519 | 0.060 |
Why?
|
| Acute Coronary Syndrome | 2 | 2024 | 2195 | 0.060 |
Why?
|
| Arteriosclerosis | 1 | 2008 | 1056 | 0.060 |
Why?
|
| Sulfasalazine | 1 | 2024 | 85 | 0.060 |
Why?
|
| Delivery of Health Care | 2 | 2019 | 5367 | 0.060 |
Why?
|
| Bacteriuria | 2 | 1995 | 102 | 0.060 |
Why?
|
| Genetics, Population | 1 | 2009 | 946 | 0.060 |
Why?
|
| Anthocyanins | 1 | 2024 | 80 | 0.060 |
Why?
|
| Residence Characteristics | 2 | 2012 | 2119 | 0.060 |
Why?
|
| Plasma Substitutes | 1 | 2003 | 58 | 0.060 |
Why?
|
| Education, Continuing | 1 | 2024 | 114 | 0.060 |
Why?
|
| Arthritis | 2 | 2008 | 685 | 0.060 |
Why?
|
| Drugs, Generic | 1 | 2009 | 454 | 0.050 |
Why?
|
| Age of Onset | 2 | 2021 | 3342 | 0.050 |
Why?
|
| Chromatography, Gas | 2 | 2014 | 150 | 0.050 |
Why?
|
| Sex Distribution | 4 | 2012 | 2286 | 0.050 |
Why?
|
| Ophthalmic Solutions | 3 | 2000 | 315 | 0.050 |
Why?
|
| Hospice Care | 1 | 2010 | 679 | 0.050 |
Why?
|
| Hemodynamics | 1 | 2014 | 4202 | 0.050 |
Why?
|
| Cerebrovascular Disorders | 4 | 2018 | 1487 | 0.050 |
Why?
|
| Receptors, Angiotensin | 1 | 2023 | 141 | 0.050 |
Why?
|
| Quality of Life | 5 | 2018 | 13497 | 0.050 |
Why?
|
| Heart-Assist Devices | 1 | 2014 | 1292 | 0.050 |
Why?
|
| Jews | 1 | 1985 | 358 | 0.050 |
Why?
|
| Cell Count | 6 | 2000 | 1835 | 0.050 |
Why?
|
| Pregnancy Outcome | 1 | 2014 | 2959 | 0.050 |
Why?
|
| Orphenadrine | 1 | 2022 | 4 | 0.050 |
Why?
|
| Chlorzoxazone | 1 | 2022 | 9 | 0.050 |
Why?
|
| Maternal-Fetal Exchange | 1 | 2005 | 462 | 0.050 |
Why?
|
| Mineral Oil | 1 | 2022 | 22 | 0.050 |
Why?
|
| Postmenopause | 3 | 2022 | 2519 | 0.050 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 3 | 2008 | 3246 | 0.050 |
Why?
|
| Isoenzymes | 2 | 2004 | 1685 | 0.050 |
Why?
|
| Aortic Diseases | 1 | 2008 | 742 | 0.050 |
Why?
|
| Diagnostic Tests, Routine | 2 | 2012 | 792 | 0.050 |
Why?
|
| Ireland | 2 | 2018 | 170 | 0.050 |
Why?
|
| Hormones | 1 | 2006 | 870 | 0.050 |
Why?
|
| Sampling Studies | 1 | 2004 | 617 | 0.050 |
Why?
|
| Antineoplastic Agents | 3 | 2015 | 13708 | 0.050 |
Why?
|
| Rate Setting and Review | 1 | 2002 | 41 | 0.050 |
Why?
|
| Dipeptidyl-Peptidases and Tripeptidyl-Peptidases | 1 | 2022 | 88 | 0.050 |
Why?
|
| Blood Component Transfusion | 1 | 2003 | 142 | 0.050 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2009 | 1209 | 0.050 |
Why?
|
| Nursing Homes | 4 | 1999 | 1084 | 0.050 |
Why?
|
| Amitriptyline | 1 | 2022 | 112 | 0.050 |
Why?
|
| Neutropenia | 2 | 2017 | 892 | 0.050 |
Why?
|
| Vestibule, Labyrinth | 2 | 2001 | 235 | 0.050 |
Why?
|
| Keratitis | 3 | 1989 | 241 | 0.050 |
Why?
|
| Nuclear Magnetic Resonance, Biomolecular | 2 | 2016 | 510 | 0.050 |
Why?
|
| Health Maintenance Organizations | 3 | 2004 | 658 | 0.050 |
Why?
|
| Narcotics | 1 | 2004 | 337 | 0.050 |
Why?
|
| Dopamine Antagonists | 1 | 2002 | 289 | 0.050 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2014 | 2040 | 0.050 |
Why?
|
| Locomotion | 2 | 1994 | 391 | 0.050 |
Why?
|
| Germany | 2 | 2018 | 882 | 0.050 |
Why?
|
| Osteoporosis, Postmenopausal | 1 | 2024 | 399 | 0.050 |
Why?
|
| Prostatic Neoplasms | 3 | 2015 | 11206 | 0.050 |
Why?
|
| Drug Synergism | 1 | 2005 | 1765 | 0.050 |
Why?
|
| Gingiva | 1 | 2004 | 423 | 0.050 |
Why?
|
| Mothers | 2 | 2022 | 2210 | 0.050 |
Why?
|
| Apolipoprotein C-III | 1 | 2022 | 210 | 0.050 |
Why?
|
| Factor VIII | 2 | 2006 | 349 | 0.050 |
Why?
|
| Postoperative Complications | 3 | 2014 | 15880 | 0.050 |
Why?
|
| Accreditation | 1 | 2024 | 478 | 0.050 |
Why?
|
| Purinergic P2Y Receptor Antagonists | 1 | 2023 | 284 | 0.050 |
Why?
|
| Magnetic Resonance Spectroscopy | 2 | 2024 | 3783 | 0.050 |
Why?
|
| Controlled Clinical Trials as Topic | 2 | 2017 | 187 | 0.050 |
Why?
|
| Polypharmacy | 2 | 2018 | 307 | 0.050 |
Why?
|
| Ventricular Function, Left | 1 | 2014 | 3941 | 0.050 |
Why?
|
| Glycosylation | 1 | 2024 | 1100 | 0.050 |
Why?
|
| Catecholamines | 1 | 2001 | 390 | 0.040 |
Why?
|
| Nutrition Assessment | 2 | 2018 | 740 | 0.040 |
Why?
|
| Education, Distance | 1 | 2024 | 261 | 0.040 |
Why?
|
| Benzimidazoles | 1 | 2006 | 864 | 0.040 |
Why?
|
| Disease-Free Survival | 3 | 2022 | 6856 | 0.040 |
Why?
|
| Muscle Relaxants, Central | 1 | 2021 | 93 | 0.040 |
Why?
|
| Long-Term Care | 2 | 2002 | 633 | 0.040 |
Why?
|
| Ventricular Remodeling | 2 | 2014 | 1280 | 0.040 |
Why?
|
| Reference Values | 6 | 2012 | 4941 | 0.040 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2009 | 3794 | 0.040 |
Why?
|
| Pulse | 1 | 2000 | 218 | 0.040 |
Why?
|
| Miotics | 1 | 2000 | 9 | 0.040 |
Why?
|
| Albuminuria | 2 | 2018 | 658 | 0.040 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 2004 | 389 | 0.040 |
Why?
|
| Terminal Care | 1 | 2012 | 1773 | 0.040 |
Why?
|
| Aldehyde Reductase | 1 | 2000 | 70 | 0.040 |
Why?
|
| Anti-Bacterial Agents | 5 | 2017 | 7471 | 0.040 |
Why?
|
| Neprilysin | 1 | 2023 | 487 | 0.040 |
Why?
|
| Weight Loss | 1 | 2012 | 2710 | 0.040 |
Why?
|
| Bronchodilator Agents | 1 | 2004 | 519 | 0.040 |
Why?
|
| Fruit | 2 | 2017 | 1165 | 0.040 |
Why?
|
| Lung Neoplasms | 4 | 2017 | 13589 | 0.040 |
Why?
|
| Renal Replacement Therapy | 1 | 2002 | 283 | 0.040 |
Why?
|
| Health Status | 5 | 2007 | 4096 | 0.040 |
Why?
|
| Alleles | 2 | 2009 | 6890 | 0.040 |
Why?
|
| Lactation | 1 | 2022 | 397 | 0.040 |
Why?
|
| Vasculitis | 1 | 2024 | 524 | 0.040 |
Why?
|
| Diabetic Angiopathies | 1 | 2005 | 806 | 0.040 |
Why?
|
| Primary Health Care | 1 | 2016 | 4737 | 0.040 |
Why?
|
| Emergency Service, Hospital | 3 | 2021 | 7956 | 0.040 |
Why?
|
| Remission Induction | 2 | 2020 | 2408 | 0.040 |
Why?
|
| Apolipoprotein A-I | 2 | 2013 | 305 | 0.040 |
Why?
|
| Prone Position | 1 | 2021 | 203 | 0.040 |
Why?
|
| Macrolides | 1 | 2021 | 205 | 0.040 |
Why?
|
| Acute Disease | 2 | 2007 | 7246 | 0.040 |
Why?
|
| Anti-Arrhythmia Agents | 1 | 2004 | 775 | 0.040 |
Why?
|
| Peripheral Arterial Disease | 1 | 2011 | 1299 | 0.040 |
Why?
|
| Myocardial Reperfusion | 1 | 2001 | 339 | 0.040 |
Why?
|
| Homes for the Aged | 2 | 1999 | 273 | 0.040 |
Why?
|
| Central Nervous System Diseases | 1 | 2004 | 521 | 0.040 |
Why?
|
| Self Report | 3 | 2019 | 3771 | 0.040 |
Why?
|
| Intraoperative Care | 1 | 2003 | 772 | 0.040 |
Why?
|
| Cost-Benefit Analysis | 4 | 2011 | 5532 | 0.040 |
Why?
|
| Anthropometry | 2 | 1983 | 1343 | 0.040 |
Why?
|
| Utah | 1 | 2019 | 130 | 0.040 |
Why?
|
| Probability | 2 | 2021 | 2483 | 0.040 |
Why?
|
| Arthralgia | 1 | 2023 | 462 | 0.040 |
Why?
|
| Stress, Psychological | 2 | 2012 | 4538 | 0.040 |
Why?
|
| Myocardial Ischemia | 1 | 2010 | 2139 | 0.040 |
Why?
|
| Ethanol | 2 | 2003 | 1334 | 0.040 |
Why?
|
| Death, Sudden | 1 | 2021 | 301 | 0.040 |
Why?
|
| Mandibular Neoplasms | 1 | 2000 | 131 | 0.040 |
Why?
|
| Excitatory Amino Acid Antagonists | 1 | 2021 | 452 | 0.040 |
Why?
|
| Child, Preschool | 9 | 2020 | 42623 | 0.040 |
Why?
|
| Clarithromycin | 1 | 2019 | 87 | 0.040 |
Why?
|
| Cardiotonic Agents | 1 | 2002 | 544 | 0.040 |
Why?
|
| Administration, Inhalation | 3 | 2008 | 1170 | 0.040 |
Why?
|
| Asthma | 3 | 2008 | 6274 | 0.040 |
Why?
|
| Meniere Disease | 1 | 2000 | 164 | 0.040 |
Why?
|
| Accidents, Home | 1 | 2018 | 73 | 0.040 |
Why?
|
| Social Environment | 1 | 1983 | 1026 | 0.040 |
Why?
|
| Women | 1 | 2000 | 225 | 0.040 |
Why?
|
| Isotretinoin | 1 | 2000 | 134 | 0.040 |
Why?
|
| Length of Stay | 4 | 2017 | 6521 | 0.040 |
Why?
|
| alpha-Tocopherol | 2 | 2008 | 126 | 0.040 |
Why?
|
| Cardiomegaly | 1 | 2001 | 591 | 0.040 |
Why?
|
| Program Development | 1 | 2024 | 1296 | 0.040 |
Why?
|
| Imidazoles | 2 | 2003 | 1174 | 0.040 |
Why?
|
| Transaminases | 1 | 2018 | 199 | 0.040 |
Why?
|
| Contraception Behavior | 1 | 2000 | 187 | 0.040 |
Why?
|
| Incus | 1 | 1997 | 19 | 0.040 |
Why?
|
| Pyuria | 2 | 1995 | 30 | 0.040 |
Why?
|
| Otitis Media, Suppurative | 1 | 1997 | 27 | 0.040 |
Why?
|
| Enalapril | 1 | 1999 | 316 | 0.040 |
Why?
|
| Ossicular Prosthesis | 1 | 1997 | 36 | 0.040 |
Why?
|
| Cardiopulmonary Bypass | 1 | 2003 | 1097 | 0.040 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2022 | 2488 | 0.040 |
Why?
|
| Motor Activity | 1 | 2007 | 2722 | 0.040 |
Why?
|
| Hospices | 2 | 2012 | 245 | 0.040 |
Why?
|
| Lung Diseases | 1 | 2008 | 1926 | 0.040 |
Why?
|
| International Cooperation | 1 | 2024 | 1439 | 0.040 |
Why?
|
| Depressive Disorder | 2 | 2005 | 3738 | 0.040 |
Why?
|
| Preventive Health Services | 1 | 2002 | 568 | 0.040 |
Why?
|
| North Carolina | 1 | 2018 | 327 | 0.040 |
Why?
|
| Ear Ossicles | 1 | 1997 | 71 | 0.040 |
Why?
|
| Narcotic Antagonists | 1 | 2022 | 590 | 0.040 |
Why?
|
| Cholesterol, VLDL | 1 | 2017 | 70 | 0.040 |
Why?
|
| Marriage | 3 | 1993 | 352 | 0.040 |
Why?
|
| Mass Screening | 1 | 1993 | 5455 | 0.040 |
Why?
|
| Motivation | 3 | 1988 | 2034 | 0.030 |
Why?
|
| Alcoholic Beverages | 1 | 1999 | 266 | 0.030 |
Why?
|
| Information Systems | 1 | 1999 | 397 | 0.030 |
Why?
|
| Mastoid | 1 | 1997 | 100 | 0.030 |
Why?
|
| Bone Conduction | 1 | 1997 | 102 | 0.030 |
Why?
|
| Reoperation | 3 | 1997 | 4342 | 0.030 |
Why?
|
| Intensive Care Units | 1 | 2010 | 3805 | 0.030 |
Why?
|
| Phacoemulsification | 1 | 1998 | 151 | 0.030 |
Why?
|
| Hearing Loss, Conductive | 1 | 1997 | 159 | 0.030 |
Why?
|
| Thrombophlebitis | 1 | 1997 | 289 | 0.030 |
Why?
|
| Prostate | 1 | 1985 | 1781 | 0.030 |
Why?
|
| Patient Participation | 1 | 2005 | 1450 | 0.030 |
Why?
|
| Republic of Korea | 1 | 2018 | 587 | 0.030 |
Why?
|
| Ultraviolet Rays | 2 | 1992 | 1100 | 0.030 |
Why?
|
| Immunoglobulin G | 2 | 2024 | 4572 | 0.030 |
Why?
|
| Eye Enucleation | 3 | 1992 | 128 | 0.030 |
Why?
|
| Femur Neck | 1 | 2017 | 319 | 0.030 |
Why?
|
| Benchmarking | 2 | 2015 | 1058 | 0.030 |
Why?
|
| Risperidone | 1 | 2018 | 383 | 0.030 |
Why?
|
| Retreatment | 2 | 2011 | 601 | 0.030 |
Why?
|
| Occupations | 2 | 2000 | 519 | 0.030 |
Why?
|
| Observer Variation | 3 | 1999 | 2622 | 0.030 |
Why?
|
| Antidepressive Agents | 2 | 2005 | 2913 | 0.030 |
Why?
|
| Ambulatory Care Facilities | 1 | 2001 | 941 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 3 | 2013 | 3816 | 0.030 |
Why?
|
| Blood Proteins | 2 | 2016 | 1183 | 0.030 |
Why?
|
| Kidney Calculi | 1 | 2019 | 469 | 0.030 |
Why?
|
| Hematologic Neoplasms | 1 | 2007 | 1905 | 0.030 |
Why?
|
| Treatment Failure | 2 | 2017 | 2656 | 0.030 |
Why?
|
| Basal Ganglia Diseases | 1 | 1995 | 145 | 0.030 |
Why?
|
| Independent Living | 1 | 2019 | 580 | 0.030 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2004 | 1891 | 0.030 |
Why?
|
| Ear, Middle | 1 | 1997 | 341 | 0.030 |
Why?
|
| Muscular Diseases | 2 | 2010 | 555 | 0.030 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2004 | 1176 | 0.030 |
Why?
|
| Hemophilia A | 1 | 1998 | 359 | 0.030 |
Why?
|
| Quality Control | 1 | 2017 | 835 | 0.030 |
Why?
|
| Otitis Media | 1 | 1997 | 288 | 0.030 |
Why?
|
| Angioplasty, Balloon, Coronary | 1 | 2001 | 1724 | 0.030 |
Why?
|
| Mouth Neoplasms | 1 | 2000 | 598 | 0.030 |
Why?
|
| Cost Savings | 3 | 2006 | 916 | 0.030 |
Why?
|
| Ibuprofen | 1 | 1996 | 229 | 0.030 |
Why?
|
| Ion Transport | 1 | 2015 | 322 | 0.030 |
Why?
|
| Vitamin D Deficiency | 1 | 2024 | 1389 | 0.030 |
Why?
|
| Kidney Function Tests | 3 | 2003 | 681 | 0.030 |
Why?
|
| Factor Analysis, Statistical | 2 | 1997 | 1007 | 0.030 |
Why?
|
| Fatty Acids, Monounsaturated | 1 | 2015 | 190 | 0.030 |
Why?
|
| Acne Vulgaris | 1 | 2000 | 351 | 0.030 |
Why?
|
| Lipoproteins | 2 | 2016 | 880 | 0.030 |
Why?
|
| Diabetic Foot | 1 | 2018 | 383 | 0.030 |
Why?
|
| Enzyme Inhibitors | 1 | 2004 | 3734 | 0.030 |
Why?
|
| Breast Feeding | 1 | 2022 | 1365 | 0.030 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2018 | 672 | 0.030 |
Why?
|
| Fishes | 1 | 2017 | 605 | 0.030 |
Why?
|
| Episode of Care | 1 | 1994 | 128 | 0.030 |
Why?
|
| Meat | 1 | 2017 | 586 | 0.030 |
Why?
|
| Dairy Products | 1 | 2017 | 490 | 0.030 |
Why?
|
| Poverty | 2 | 2018 | 2719 | 0.030 |
Why?
|
| Binomial Distribution | 1 | 1993 | 23 | 0.030 |
Why?
|
| Technetium Tc 99m Sestamibi | 1 | 2014 | 184 | 0.030 |
Why?
|
| Hearing | 1 | 1997 | 502 | 0.030 |
Why?
|
| Leukocyte Count | 2 | 1990 | 1604 | 0.030 |
Why?
|
| Obesity, Morbid | 1 | 2024 | 1309 | 0.030 |
Why?
|
| Maternal Behavior | 1 | 2015 | 309 | 0.030 |
Why?
|
| Speech Reception Threshold Test | 1 | 1992 | 16 | 0.030 |
Why?
|
| Speech Discrimination Tests | 1 | 1992 | 35 | 0.030 |
Why?
|
| Angina Pectoris | 1 | 1997 | 960 | 0.030 |
Why?
|
| Lymphocytes | 1 | 2021 | 2611 | 0.030 |
Why?
|
| Cardiovascular System | 1 | 2020 | 838 | 0.030 |
Why?
|
| Enzyme Induction | 1 | 2013 | 455 | 0.030 |
Why?
|
| Audiometry, Evoked Response | 1 | 1992 | 45 | 0.030 |
Why?
|
| Radiotherapy | 1 | 2019 | 1510 | 0.030 |
Why?
|
| Dark Adaptation | 1 | 1993 | 224 | 0.030 |
Why?
|
| Palmitic Acid | 1 | 2013 | 149 | 0.030 |
Why?
|
| Joint Diseases | 1 | 1996 | 460 | 0.030 |
Why?
|
| Sensory Thresholds | 1 | 1993 | 377 | 0.020 |
Why?
|
| Prediabetic State | 1 | 2018 | 548 | 0.020 |
Why?
|
| Prosthesis Failure | 1 | 1997 | 1208 | 0.020 |
Why?
|
| Therapeutic Equivalency | 2 | 2002 | 134 | 0.020 |
Why?
|
| Linoleic Acid | 1 | 2013 | 159 | 0.020 |
Why?
|
| Health Planning Support | 1 | 2011 | 9 | 0.020 |
Why?
|
| Hyperuricemia | 1 | 2015 | 223 | 0.020 |
Why?
|
| Death Certificates | 2 | 2006 | 175 | 0.020 |
Why?
|
| Validation Studies as Topic | 1 | 2012 | 162 | 0.020 |
Why?
|
| Half-Life | 2 | 2004 | 650 | 0.020 |
Why?
|
| Haplotypes | 2 | 2008 | 2725 | 0.020 |
Why?
|
| Vegetables | 1 | 2017 | 1202 | 0.020 |
Why?
|
| Population Surveillance | 2 | 1999 | 2601 | 0.020 |
Why?
|
| Electroretinography | 1 | 1993 | 524 | 0.020 |
Why?
|
| Medicare Part B | 1 | 2012 | 117 | 0.020 |
Why?
|
| Guidelines as Topic | 1 | 2018 | 1395 | 0.020 |
Why?
|
| Nonprescription Drugs | 1 | 1992 | 119 | 0.020 |
Why?
|
| Retinal Detachment | 3 | 1990 | 429 | 0.020 |
Why?
|
| Neurodegenerative Diseases | 1 | 2020 | 1095 | 0.020 |
Why?
|
| Dextropropoxyphene | 1 | 2010 | 26 | 0.020 |
Why?
|
| Depressive Disorder, Major | 1 | 2009 | 4816 | 0.020 |
Why?
|
| Thiazolidinediones | 1 | 2014 | 462 | 0.020 |
Why?
|
| Adenine | 1 | 2017 | 993 | 0.020 |
Why?
|
| Managed Care Programs | 1 | 1996 | 941 | 0.020 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 1993 | 395 | 0.020 |
Why?
|
| Intention to Treat Analysis | 1 | 2012 | 417 | 0.020 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2013 | 423 | 0.020 |
Why?
|
| Codeine | 1 | 2010 | 51 | 0.020 |
Why?
|
| Disabled Persons | 1 | 2000 | 1218 | 0.020 |
Why?
|
| Eye Color | 1 | 1990 | 35 | 0.020 |
Why?
|
| Chemoprevention | 1 | 2013 | 326 | 0.020 |
Why?
|
| Nootropic Agents | 1 | 2012 | 159 | 0.020 |
Why?
|
| Creatine Kinase | 2 | 2004 | 685 | 0.020 |
Why?
|
| False Negative Reactions | 1 | 2012 | 575 | 0.020 |
Why?
|
| Adaptation, Psychological | 1 | 2021 | 2665 | 0.020 |
Why?
|
| Self Administration | 3 | 1998 | 387 | 0.020 |
Why?
|
| Premenopause | 1 | 2015 | 1039 | 0.020 |
Why?
|
| Qualitative Research | 1 | 2021 | 3115 | 0.020 |
Why?
|
| Exercise Test | 1 | 2018 | 2186 | 0.020 |
Why?
|
| Peptides | 1 | 2022 | 4368 | 0.020 |
Why?
|
| Vitamin K | 1 | 1993 | 314 | 0.020 |
Why?
|
| Blood Chemical Analysis | 1 | 2012 | 436 | 0.020 |
Why?
|
| Asymptomatic Diseases | 1 | 2013 | 591 | 0.020 |
Why?
|
| Musculoskeletal Diseases | 1 | 1996 | 601 | 0.020 |
Why?
|
| Liability, Legal | 1 | 2011 | 208 | 0.020 |
Why?
|
| Heterozygote | 1 | 1997 | 2792 | 0.020 |
Why?
|
| SEER Program | 1 | 2015 | 1476 | 0.020 |
Why?
|
| Otolaryngology | 1 | 1997 | 698 | 0.020 |
Why?
|
| Classification | 1 | 1990 | 128 | 0.020 |
Why?
|
| Early Termination of Clinical Trials | 1 | 2010 | 70 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2017 | 2944 | 0.020 |
Why?
|
| Drug Recalls | 1 | 2009 | 20 | 0.020 |
Why?
|
| Echocardiography, Doppler | 1 | 2014 | 899 | 0.020 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 1 | 2005 | 3742 | 0.020 |
Why?
|
| Single-Blind Method | 1 | 2013 | 1585 | 0.020 |
Why?
|
| Ciliary Body | 1 | 1990 | 168 | 0.020 |
Why?
|
| Neuropsychological Tests | 2 | 2001 | 7134 | 0.020 |
Why?
|
| Elastic Tissue | 1 | 1989 | 66 | 0.020 |
Why?
|
| Thrombocytopenia | 1 | 2017 | 1183 | 0.020 |
Why?
|
| Drug Substitution | 1 | 2012 | 291 | 0.020 |
Why?
|
| Iris | 1 | 1990 | 231 | 0.020 |
Why?
|
| Upper Gastrointestinal Tract | 1 | 2009 | 46 | 0.020 |
Why?
|
| Neoplasm Staging | 2 | 2015 | 11249 | 0.020 |
Why?
|
| Particle Size | 1 | 2013 | 1654 | 0.020 |
Why?
|
| Coronary Angiography | 2 | 2016 | 4526 | 0.020 |
Why?
|
| Choroid Neoplasms | 1 | 1990 | 177 | 0.020 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2013 | 647 | 0.020 |
Why?
|
| Denmark | 1 | 2011 | 778 | 0.020 |
Why?
|
| Food Handling | 1 | 2009 | 158 | 0.020 |
Why?
|
| Macula Lutea | 2 | 1987 | 180 | 0.020 |
Why?
|
| Health Plan Implementation | 1 | 2012 | 338 | 0.020 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2012 | 794 | 0.020 |
Why?
|
| Social Support | 2 | 2002 | 2195 | 0.020 |
Why?
|
| Hirudins | 1 | 2009 | 179 | 0.020 |
Why?
|
| Blindness | 1 | 1992 | 588 | 0.020 |
Why?
|
| Factor VII | 1 | 2009 | 139 | 0.020 |
Why?
|
| Protein Precursors | 1 | 1993 | 1133 | 0.020 |
Why?
|
| Beverages | 1 | 1994 | 822 | 0.020 |
Why?
|
| Nebulizers and Vaporizers | 1 | 2009 | 139 | 0.020 |
Why?
|
| Temperance | 1 | 1988 | 88 | 0.020 |
Why?
|
| Heart Conduction System | 1 | 1994 | 1009 | 0.020 |
Why?
|
| Financing, Government | 1 | 2012 | 473 | 0.020 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2018 | 6035 | 0.020 |
Why?
|
| Piperidines | 1 | 2017 | 1664 | 0.020 |
Why?
|
| Lumbar Vertebrae | 1 | 2017 | 1885 | 0.020 |
Why?
|
| Argon | 1 | 1987 | 36 | 0.020 |
Why?
|
| Xanthophylls | 1 | 2008 | 95 | 0.020 |
Why?
|
| Angiotensinogen | 1 | 2008 | 161 | 0.020 |
Why?
|
| Meta-Analysis as Topic | 1 | 2013 | 1364 | 0.020 |
Why?
|
| Hair Cells, Auditory | 1 | 1990 | 383 | 0.020 |
Why?
|
| Rectal Neoplasms | 1 | 2017 | 1179 | 0.020 |
Why?
|
| Pregnancy Trimester, First | 1 | 2012 | 918 | 0.020 |
Why?
|
| Health Status Disparities | 1 | 2019 | 1876 | 0.020 |
Why?
|
| Receptor, Angiotensin, Type 1 | 1 | 2008 | 153 | 0.020 |
Why?
|
| Rural Population | 1 | 2018 | 2317 | 0.020 |
Why?
|
| Poisoning | 1 | 2009 | 252 | 0.020 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2017 | 2847 | 0.020 |
Why?
|
| Lutein | 1 | 2008 | 123 | 0.020 |
Why?
|
| Texas | 1 | 2008 | 405 | 0.020 |
Why?
|
| Sclera | 1 | 1989 | 190 | 0.020 |
Why?
|
| Medicare Part C | 1 | 2012 | 332 | 0.020 |
Why?
|
| Nephelometry and Turbidimetry | 1 | 2007 | 91 | 0.020 |
Why?
|
| Feeding Behavior | 2 | 2011 | 3202 | 0.020 |
Why?
|
| Diagnostic Techniques and Procedures | 1 | 2009 | 219 | 0.020 |
Why?
|
| Physicians, Family | 1 | 2009 | 349 | 0.020 |
Why?
|
| Sulfoxides | 1 | 2006 | 47 | 0.020 |
Why?
|
| Hypoglycemia | 1 | 1994 | 894 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2015 | 4138 | 0.020 |
Why?
|
| Fovea Centralis | 1 | 1987 | 126 | 0.020 |
Why?
|
| 2-Pyridinylmethylsulfinylbenzimidazoles | 1 | 2006 | 32 | 0.020 |
Why?
|
| Stents | 1 | 2018 | 3204 | 0.020 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2008 | 588 | 0.020 |
Why?
|
| State Health Plans | 1 | 2008 | 220 | 0.020 |
Why?
|
| Death | 1 | 2010 | 683 | 0.020 |
Why?
|
| Solubility | 1 | 2007 | 1086 | 0.020 |
Why?
|
| Atrophy | 1 | 1990 | 1648 | 0.020 |
Why?
|
| Hospitals | 1 | 2019 | 3906 | 0.020 |
Why?
|
| Phospholipases A2 | 1 | 2005 | 197 | 0.020 |
Why?
|
| Carcinoma, Merkel Cell | 1 | 1989 | 331 | 0.020 |
Why?
|
| Databases, Bibliographic | 1 | 2005 | 130 | 0.020 |
Why?
|
| Patient Readmission | 1 | 2019 | 3308 | 0.020 |
Why?
|
| Emphysema | 1 | 2008 | 238 | 0.020 |
Why?
|
| Coronary Vessels | 1 | 2016 | 3122 | 0.020 |
Why?
|
| Internal Medicine | 1 | 2012 | 1056 | 0.020 |
Why?
|
| Adiposity | 1 | 2015 | 1888 | 0.010 |
Why?
|
| Cochlear Implants | 1 | 1989 | 343 | 0.010 |
Why?
|
| Proton Pump Inhibitors | 1 | 2009 | 552 | 0.010 |
Why?
|
| Hospitals, Teaching | 2 | 2001 | 1158 | 0.010 |
Why?
|
| Hospital Records | 1 | 2004 | 93 | 0.010 |
Why?
|
| Hyperglycemia | 1 | 1993 | 1389 | 0.010 |
Why?
|
| Creatine Kinase, MB Form | 1 | 2004 | 202 | 0.010 |
Why?
|
| Administration, Topical | 2 | 1997 | 707 | 0.010 |
Why?
|
| Quality Improvement | 1 | 2019 | 3858 | 0.010 |
Why?
|
| Aerosols | 1 | 2006 | 637 | 0.010 |
Why?
|
| Interleukin-10 | 1 | 2009 | 1185 | 0.010 |
Why?
|
| Pruritus | 1 | 2006 | 380 | 0.010 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 1 | 2004 | 318 | 0.010 |
Why?
|
| Connecticut | 2 | 1994 | 365 | 0.010 |
Why?
|
| Urban Population | 2 | 1988 | 2047 | 0.010 |
Why?
|
| Hemodialysis Units, Hospital | 1 | 2002 | 22 | 0.010 |
Why?
|
| Hemodialysis, Home | 1 | 2002 | 21 | 0.010 |
Why?
|
| Medical Audit | 1 | 2004 | 454 | 0.010 |
Why?
|
| Peritoneal Dialysis, Continuous Ambulatory | 1 | 2002 | 28 | 0.010 |
Why?
|
| Edetic Acid | 1 | 2003 | 278 | 0.010 |
Why?
|
| Scotland | 1 | 2002 | 143 | 0.010 |
Why?
|
| Optic Disk | 1 | 1987 | 422 | 0.010 |
Why?
|
| Postoperative Period | 1 | 1987 | 1833 | 0.010 |
Why?
|
| Life Tables | 1 | 2002 | 368 | 0.010 |
Why?
|
| Software Design | 1 | 2002 | 173 | 0.010 |
Why?
|
| Risk-Taking | 1 | 1988 | 1041 | 0.010 |
Why?
|
| Receptor, erbB-2 | 1 | 2013 | 2586 | 0.010 |
Why?
|
| Value of Life | 1 | 2002 | 98 | 0.010 |
Why?
|
| Naproxen | 1 | 2002 | 101 | 0.010 |
Why?
|
| Interpersonal Relations | 2 | 1993 | 1439 | 0.010 |
Why?
|
| Ceftazidime | 1 | 2001 | 57 | 0.010 |
Why?
|
| Chicago | 1 | 2002 | 255 | 0.010 |
Why?
|
| Economics, Pharmaceutical | 1 | 2002 | 88 | 0.010 |
Why?
|
| Cyclooxygenase 2 | 1 | 2004 | 599 | 0.010 |
Why?
|
| Heart Ventricles | 1 | 2014 | 3839 | 0.010 |
Why?
|
| Ofloxacin | 1 | 2001 | 66 | 0.010 |
Why?
|
| Hyperplasia | 1 | 1985 | 1154 | 0.010 |
Why?
|
| Hospitals, Veterans | 1 | 2004 | 395 | 0.010 |
Why?
|
| Social Values | 1 | 2002 | 225 | 0.010 |
Why?
|
| Physician-Patient Relations | 2 | 2005 | 3267 | 0.010 |
Why?
|
| Ankylosis | 1 | 2001 | 39 | 0.010 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2014 | 3408 | 0.010 |
Why?
|
| Epoprostenol | 1 | 2001 | 248 | 0.010 |
Why?
|
| Prolactin | 1 | 2002 | 626 | 0.010 |
Why?
|
| Reference Standards | 1 | 2004 | 1015 | 0.010 |
Why?
|
| Troponin | 1 | 2004 | 534 | 0.010 |
Why?
|
| Placebo Effect | 1 | 2004 | 518 | 0.010 |
Why?
|
| Streptomycin | 1 | 2000 | 69 | 0.010 |
Why?
|
| Kanamycin | 1 | 2000 | 63 | 0.010 |
Why?
|
| Bacterial Infections | 1 | 1989 | 1397 | 0.010 |
Why?
|
| Time | 1 | 2002 | 546 | 0.010 |
Why?
|
| Neomycin | 1 | 2000 | 94 | 0.010 |
Why?
|
| Tars | 1 | 1980 | 20 | 0.010 |
Why?
|
| Walking | 1 | 2007 | 1202 | 0.010 |
Why?
|
| Cephalosporins | 1 | 2001 | 200 | 0.010 |
Why?
|
| Pain Measurement | 1 | 2010 | 3577 | 0.010 |
Why?
|
| Caffeine | 1 | 1985 | 702 | 0.010 |
Why?
|
| MEDLINE | 1 | 2000 | 119 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2009 | 6527 | 0.010 |
Why?
|
| Technology Assessment, Biomedical | 1 | 2002 | 308 | 0.010 |
Why?
|
| Premature Birth | 1 | 2012 | 1816 | 0.010 |
Why?
|
| Cost Control | 1 | 2002 | 627 | 0.010 |
Why?
|
| Vaginal Smears | 1 | 2002 | 501 | 0.010 |
Why?
|
| Joints | 1 | 2001 | 324 | 0.010 |
Why?
|
| Blood Urea Nitrogen | 1 | 1999 | 187 | 0.010 |
Why?
|
| Multiple Sclerosis | 1 | 2014 | 3245 | 0.010 |
Why?
|
| Norepinephrine | 1 | 2001 | 900 | 0.010 |
Why?
|
| Dementia, Vascular | 1 | 2000 | 125 | 0.010 |
Why?
|
| Arteriovenous Shunt, Surgical | 1 | 2002 | 291 | 0.010 |
Why?
|
| Exfoliation Syndrome | 1 | 2000 | 113 | 0.010 |
Why?
|
| Physician's Role | 1 | 2005 | 927 | 0.010 |
Why?
|
| Protons | 3 | 1989 | 1113 | 0.010 |
Why?
|
| Keratins | 1 | 2000 | 502 | 0.010 |
Why?
|
| Angiotensin II | 1 | 2001 | 849 | 0.010 |
Why?
|
| Marital Status | 1 | 2000 | 426 | 0.010 |
Why?
|
| Beer | 1 | 1999 | 135 | 0.010 |
Why?
|
| Neurologic Examination | 1 | 2001 | 916 | 0.010 |
Why?
|
| Wine | 1 | 1999 | 172 | 0.010 |
Why?
|
| Epinephrine | 1 | 2001 | 795 | 0.010 |
Why?
|
| Photography | 2 | 1992 | 537 | 0.010 |
Why?
|
| Biopsy | 3 | 1999 | 6816 | 0.010 |
Why?
|
| Thorax | 1 | 1981 | 559 | 0.010 |
Why?
|
| Netherlands | 1 | 2002 | 2274 | 0.010 |
Why?
|
| Blood Pressure Determination | 1 | 2001 | 646 | 0.010 |
Why?
|
| Hormone Replacement Therapy | 1 | 2003 | 756 | 0.010 |
Why?
|
| Granulation Tissue | 1 | 1997 | 92 | 0.010 |
Why?
|
| Burns | 1 | 2009 | 1887 | 0.010 |
Why?
|
| Catheterization, Central Venous | 1 | 2002 | 530 | 0.010 |
Why?
|
| Medical Staff, Hospital | 1 | 2001 | 603 | 0.010 |
Why?
|
| Cholesteatoma, Middle Ear | 1 | 1997 | 52 | 0.010 |
Why?
|
| Tobacco Use Disorder | 1 | 1983 | 710 | 0.010 |
Why?
|
| Blood Vessel Prosthesis | 1 | 2002 | 959 | 0.010 |
Why?
|
| Population | 1 | 1997 | 141 | 0.010 |
Why?
|
| Troponin I | 1 | 2001 | 662 | 0.010 |
Why?
|
| Apolipoproteins E | 1 | 2003 | 1461 | 0.010 |
Why?
|
| Protein C | 1 | 1997 | 134 | 0.010 |
Why?
|
| Epilepsy | 1 | 2012 | 3324 | 0.010 |
Why?
|
| Medical Oncology | 1 | 2008 | 2347 | 0.010 |
Why?
|
| Family Health | 1 | 2001 | 1256 | 0.010 |
Why?
|
| Ear Canal | 1 | 1997 | 149 | 0.010 |
Why?
|
| Wounds and Injuries | 1 | 2009 | 2518 | 0.010 |
Why?
|
| Ultrasonography | 1 | 1989 | 5995 | 0.010 |
Why?
|
| Psychotropic Drugs | 1 | 2001 | 888 | 0.010 |
Why?
|
| Interviews as Topic | 2 | 1996 | 2733 | 0.010 |
Why?
|
| Reagent Strips | 1 | 1995 | 40 | 0.010 |
Why?
|
| Carboxylic Ester Hydrolases | 1 | 1995 | 99 | 0.010 |
Why?
|
| Lipid Metabolism | 1 | 2003 | 1898 | 0.010 |
Why?
|
| Weight Gain | 1 | 2005 | 2357 | 0.010 |
Why?
|
| Nicotine | 1 | 1980 | 681 | 0.010 |
Why?
|
| Colony Count, Microbial | 1 | 1995 | 329 | 0.010 |
Why?
|
| Dopamine Agents | 1 | 1995 | 190 | 0.010 |
Why?
|
| Dopamine | 1 | 2001 | 1616 | 0.010 |
Why?
|
| Respiration | 1 | 1981 | 1667 | 0.010 |
Why?
|
| Nutritional Requirements | 1 | 1996 | 279 | 0.010 |
Why?
|
| Cell Size | 1 | 1996 | 626 | 0.010 |
Why?
|
| Anti-Infective Agents | 1 | 2001 | 987 | 0.010 |
Why?
|
| Noise | 1 | 1996 | 292 | 0.010 |
Why?
|
| Psychological Tests | 1 | 1996 | 643 | 0.010 |
Why?
|
| Renin | 1 | 1996 | 642 | 0.010 |
Why?
|
| Teaching | 1 | 2001 | 1174 | 0.010 |
Why?
|
| Attitude to Health | 1 | 2002 | 2030 | 0.010 |
Why?
|
| Intestinal Polyps | 1 | 1993 | 105 | 0.010 |
Why?
|
| Iowa | 1 | 1992 | 104 | 0.010 |
Why?
|
| Microscopy, Electron | 1 | 1996 | 2565 | 0.010 |
Why?
|
| Prostate-Specific Antigen | 1 | 2002 | 2483 | 0.010 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 1989 | 9066 | 0.010 |
Why?
|
| Mutation | 1 | 1997 | 30243 | 0.010 |
Why?
|
| Postal Service | 1 | 1992 | 96 | 0.010 |
Why?
|
| Arteries | 1 | 1997 | 1126 | 0.010 |
Why?
|
| Skin Transplantation | 1 | 1997 | 1097 | 0.010 |
Why?
|
| Urinalysis | 1 | 1994 | 369 | 0.010 |
Why?
|
| Neoplasm Invasiveness | 1 | 2000 | 3637 | 0.010 |
Why?
|
| Mammography | 1 | 2002 | 2436 | 0.010 |
Why?
|
| Escherichia coli Infections | 1 | 1995 | 524 | 0.010 |
Why?
|
| Recovery of Function | 1 | 2001 | 2994 | 0.010 |
Why?
|
| Health Promotion | 1 | 2002 | 2215 | 0.010 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2005 | 3682 | 0.010 |
Why?
|
| Vital Capacity | 2 | 1984 | 984 | 0.010 |
Why?
|
| Glaucoma, Neovascular | 1 | 1989 | 37 | 0.010 |
Why?
|
| Estrogens | 1 | 1996 | 1531 | 0.010 |
Why?
|
| Altitude | 1 | 1990 | 164 | 0.010 |
Why?
|
| Hygiene | 1 | 1989 | 95 | 0.010 |
Why?
|
| Compliance | 1 | 1989 | 100 | 0.010 |
Why?
|
| Nerve Tissue Proteins | 1 | 2001 | 4417 | 0.000 |
Why?
|
| Urinary Tract Infections | 1 | 1995 | 806 | 0.000 |
Why?
|
| Mental Disorders | 1 | 2008 | 6879 | 0.000 |
Why?
|
| Sunlight | 1 | 1990 | 337 | 0.000 |
Why?
|
| Adipose Tissue | 1 | 2000 | 3335 | 0.000 |
Why?
|
| Histological Techniques | 1 | 1988 | 194 | 0.000 |
Why?
|
| Demography | 1 | 1993 | 1643 | 0.000 |
Why?
|
| Cerebral Hemorrhage | 1 | 1999 | 2665 | 0.000 |
Why?
|
| Animals | 2 | 2017 | 169418 | 0.000 |
Why?
|
| Axons | 1 | 1996 | 1678 | 0.000 |
Why?
|
| Knee Joint | 1 | 1996 | 1683 | 0.000 |
Why?
|
| Membrane Proteins | 1 | 2004 | 7895 | 0.000 |
Why?
|
| Iris Diseases | 1 | 1987 | 36 | 0.000 |
Why?
|
| Personality | 1 | 1990 | 558 | 0.000 |
Why?
|
| Hand | 1 | 1992 | 907 | 0.000 |
Why?
|
| Memory | 1 | 1996 | 2210 | 0.000 |
Why?
|
| Immunohistochemistry | 1 | 2000 | 11138 | 0.000 |
Why?
|
| Medical History Taking | 1 | 1990 | 776 | 0.000 |
Why?
|
| Social Adjustment | 1 | 1988 | 636 | 0.000 |
Why?
|
| Lung | 1 | 1984 | 10090 | 0.000 |
Why?
|
| Liver Neoplasms | 2 | 1992 | 4362 | 0.000 |
Why?
|
| Staining and Labeling | 1 | 1989 | 1083 | 0.000 |
Why?
|
| Maximal Expiratory Flow Rate | 1 | 1984 | 42 | 0.000 |
Why?
|
| Eye | 1 | 1989 | 715 | 0.000 |
Why?
|
| Bacteria | 1 | 1995 | 2226 | 0.000 |
Why?
|
| Physical Examination | 1 | 1990 | 1262 | 0.000 |
Why?
|
| Diagnosis, Differential | 1 | 1999 | 13026 | 0.000 |
Why?
|
| Cell Survival | 1 | 1993 | 5801 | 0.000 |
Why?
|
| Orosomucoid | 1 | 1982 | 45 | 0.000 |
Why?
|
| Pedigree | 1 | 1990 | 4545 | 0.000 |
Why?
|
| Complement Factor B | 1 | 1982 | 57 | 0.000 |
Why?
|
| alpha 1-Antitrypsin | 1 | 1982 | 169 | 0.000 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2000 | 9425 | 0.000 |
Why?
|
| Spirometry | 1 | 1984 | 928 | 0.000 |
Why?
|
| Haptoglobins | 1 | 1982 | 165 | 0.000 |
Why?
|
| Cornea | 1 | 1989 | 1332 | 0.000 |
Why?
|
| Skinfold Thickness | 1 | 1981 | 163 | 0.000 |
Why?
|
| Internship and Residency | 1 | 2001 | 5952 | 0.000 |
Why?
|
| Retinal Diseases | 1 | 1987 | 711 | 0.000 |
Why?
|
| Platelet Function Tests | 1 | 1982 | 272 | 0.000 |
Why?
|
| Neoplasm Metastasis | 1 | 1991 | 4931 | 0.000 |
Why?
|
| Platelet Count | 1 | 1982 | 786 | 0.000 |
Why?
|
| Platelet Aggregation | 1 | 1982 | 772 | 0.000 |
Why?
|
| Life Change Events | 1 | 1984 | 964 | 0.000 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 1983 | 628 | 0.000 |
Why?
|
| Collagen | 1 | 1982 | 2646 | 0.000 |
Why?
|